

1 A comprehensive antigen production and characterization study for easy-to- 2 implement, highly specific and quantitative SARS-CoV-2 antibody assays

3
4 Miriam Klausberger^{1†}, Mark Dürkop^{1,2†}, Helmuth Haslacher³, Gordana Wozniak-Knopp^{1,4}, Monika Cserjan-
5 Puschmann^{1,5}, Thomas Perkmann³, Nico Lingg^{1,5}, Patricia Pereira Aguilar^{1,5}, Elisabeth Laurent^{1,6}, Jelle De
6 Vos^{1,7}, Manuela Hofer⁸, Barbara Holzer⁹, Maria Stadler¹⁰, Gabriele Manhart¹¹, Klemens Vierlinger⁸, Margot
7 Egger¹², Lisa Milchram⁸, Elisabeth Gludovacz¹, Nicolas Marx¹, Christoph Köppl^{1,5}, Christopher Tauer¹,
8 Jürgen Beck¹, Daniel Maresch¹³, Clemens Grünwald-Gruber^{13,14}, Florian Strobl¹⁵, Peter Satzer^{1,5}, Gerhard
9 Stadlmayr^{1,4}, Ulrike Vavra¹⁶, Jasmin Huber⁸, Markus Wahrmann¹⁷, Farsad Eskandary¹⁷, Marie-Kathrin
10 Breyer¹⁸, Daniela Sieghart¹⁹, Peter Quehenberger³, Gerda Leitner²⁰, Robert Strassl³, Alexander E. Egger²¹,
11 Christian Irsara²¹, Andrea Griesmacher²¹, Gregor Hoermann^{21,22}, Günter Weiss²³, Rosa Bellmann-Weiler²³,
12 Judith Loeffler-Ragg^{23‡}, Nicole Borth¹, Richard Strasser¹⁶, Alois Jungbauer^{1,5}, Rainer Hahn^{1,5}, Jürgen
13 Mairhofer¹⁵, Boris Hartmann⁹, Nikolaus B. Binder²⁴, Gerald Striedner^{1,2,5,15}, Lukas Mach¹⁶, Andreas
14 Weinhäusl⁸, Benjamin Dieplinger¹², Florian Grebien^{11*}, Wilhelm Gerner^{10,25,26¶} and Christoph J. Binder^{3¶*}
15 and Reingard Grabherr^{1¶*}

16
17 ¹ Department of Biotechnology, University of Natural Resources and Life Sciences (BOKU) Vienna, Austria.

18 ² Novasign GmbH Vienna, Austria.

19 ³ Department of Laboratory Medicine, Medical University of Vienna, Austria.

20 ⁴ CD Laboratory for innovative Immunotherapeutics, Vienna, Austria.

21 ⁵ ACIB-Austrian Centre of Industrial Biotechnology, Graz, Austria.

22 ⁶ BOKU Core Facility Biomolecular & Cellular Analysis, University of Natural Resources and Life Sciences Vienna, Austria.

23 ⁷ Department of Chemical Engineering, Vrije Universiteit Brussel (VUB), Brussels, Belgium.

24 ⁸ Competence Unit Molecular Diagnostics, Center for Health and Bioresources, AIT Austrian Institute of Technology GmbH, Vienna, Austria.

25 ⁹ Austrian Agency for Health and Food Safety (AGES), Department for Animal Health, Moedling, Austria.

26 ¹⁰ Institute of Immunology, University of Veterinary Medicine Vienna, Austria.

27 ¹¹ Institute for Medical Biochemistry, University of Veterinary Medicine, Vienna, Austria.

28 ¹² Department of Laboratory Medicine, Konventhospital Barmherzige Brüeder Linz and Ordensklinikum Linz Barmherzige Schwestern, Linz,
29 Austria.

30 ¹³ BOKU Core Facility Mass Spectrometry, University of Natural Resources and Life Sciences, Vienna, Austria.

31 ¹⁴ Department of Chemistry (BOKU), University of Natural Resources and Life Sciences Vienna, Austria.

32 ¹⁵ enGenes Biotech GmbH, Vienna, Austria.

33 ¹⁶ Department of Applied Genetics and Cell Biology (DAGZ), University of Natural Resources and Life Sciences (BOKU) Vienna, Austria.

34 ¹⁷ Department of Medicine III, Division of Nephrology and Dialysis, Medical University Vienna, Austria.

35 ¹⁸ Department of Respiratory and Critical Care Medicine and Ludwig Boltzmann Institute for Lung Health, Otto Wagner Hospital, Vienna, Austria.

36 ¹⁹ Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Austria.

37 ²⁰ Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Austria.

38 ²¹ Central Institute for Medical and Chemical Laboratory Diagnosis, Innsbruck University Hospital, Innsbruck, Austria.

39 ²² MLL Munich Leukemia Laboratory, Munich, Germany.

40 ²³ Department of Internal Medicine II, Innsbruck Medical University, Austria.

41 ²⁴ Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH, Vienna, Austria.

42 ²⁵ Christian Doppler Laboratory for an Optimized Prediction of Vaccination Success in Pigs, University of Veterinary Medicine, Vienna, Austria.

43 ²⁶ The Pirbright Institute, Pirbright, United Kingdom.

44
45 † authors contributed equally

46 ‡ on behalf of the CovILD study group

47 ¶ authors contributed equally

48 * Corresponding authors

49
50
51 *Corresponding authors: Email: FS: florian.grebien@vetmeduni.ac.at

52 CJB: christoph.binder@medunivie.ac.at

53 RG: reingard.grabherr@boku.ac.at

54 **Abstract**

55 Antibody tests are essential tools to investigate humoral immunity following SARS-CoV-2 infection. While
56 first-generation antibody tests have primarily provided qualitative results with low specificity, accurate
57 seroprevalence studies and tracking of antibody levels over time require highly specific, sensitive and
58 quantitative test setups. Here, we describe two quantitative ELISA antibody tests based on the SARS-CoV-
59 2 spike receptor-binding domain and the nucleocapsid protein. Comparative expression in bacterial,
60 insect, mammalian and plant-based platforms enabled the identification of new antigen designs with
61 superior quality and high suitability as diagnostic reagents. Both tests scored excellently in clinical
62 validations with multi-centric specificity and sensitivity cohorts and showed unprecedented correlation
63 with SARS-CoV-2 neutralization titers. Orthogonal testing increased assay specificity to 99.8%, thereby
64 enabling robust serodiagnosis in low-prevalence settings. The inclusion of a calibrator permits accurate
65 quantitative monitoring of antibody concentrations in samples collected at different time points during
66 the acute and convalescent phase of COVID-19.

67 1. Introduction

68 Serological testing of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections remains
69 an essential tool for seroprevalence studies and complements PCR-based diagnosis in identifying
70 asymptomatic individuals (1). Antibody tests are gaining additional importance as means to characterize
71 the extent of infection- or vaccine-induced immunity. To cope with the urgent demand for sensitive and
72 reliable test systems, many manual and automated serological tests for coronavirus disease 2019 (COVID-
73 19) became available within a short period of time (2). Owing to the acuity of a spreading pandemic, many
74 of these early developed test systems lacked adequate validation and thereby fueled mistrust, while
75 stocks of others were exhausted rapidly due to increased demand (3).

76 Antigen selection and quality are crucial aspects of assay development and influence diagnostic
77 performance (4), such as sensitivity and specificity as well as assay availability, scalability and their field
78 of application. Ideal candidate antigens for *in-vitro* serodiagnosis are highly immunogenic, support early
79 and robust detection of seroconversion after an infection and result in low false positivity rates.
80 Additionally, production platforms supporting high process yields ensure sustainable assay supply. To
81 date, biotechnological performance attributes and their influence on serodiagnostics were not reported
82 during the development of assays for SARS-CoV-2 detection. Likewise, no comprehensive study comparing
83 and validating the same SARS-CoV-2 antigen produced in different expression systems with larger cohorts
84 is available.

85 In this study, we developed two quantitative, enzyme-linked immunosorbent assay (ELISA)-based
86 serotests relying on SARS-CoV-2 receptor-binding domain (RBD) and nucleocapsid protein (NP) antigens
87 of superior design and quality. Since these assays utilize established ELISA technology, they are easy to
88 implement in any lab worldwide. We describe a comprehensive approach assessing biotechnological
89 parameters such as antigen quality attributes and manufacturability for an ideal test setup. For this

90 purpose, we compared several animal cell lines and plant-based expression platforms for their ability to
91 support high-quantity and quality RBD production and assessed whether the employed production host
92 influences antigen performance. We extensively validated the tests for clinical utility featuring sera from
93 individuals covering the full spectrum of disease presentations at different time points post infection and
94 a large specificity cohort including samples with antibodies towards human coronaviruses (hCoVs) and
95 those from individuals with underlying non-infectious diseases. Moreover, we validated the tests with
96 time-resolved acute and early convalescent samples from hospitalized patients and showed that only
97 RBD-specific antibodies demonstrate excellent correlation with neutralization assays already in the early
98 phase of infection.

99 2. Results

100 **Comparative profiling of expression hosts for SARS CoV-2 RBD and NP production for diagnostic use**

101 Initially, five eukaryotic expression systems were compared for their capacity to support high-quantity
102 and high-quality expression of the glycosylated SARS-CoV-2 spike RBD. Our pre-defined quality attributes
103 covered activity in a functional binding assay using a conformation-dependent RBD-specific antibody
104 (CR3022), protein integrity and glycosylation determined by mass spectrometry, as well as
105 manufacturability (**Fig. 1A**). Biolayer interferometry analysis revealed that RBD obtained from different
106 mammalian and insect expression systems have comparable affinities (range: 21 – 43 nM) for the mAb
107 CR3022 (**Fig. 1A, left panel**). Glycan analysis confirmed host-specific N-glycosylation of the respective
108 proteins, which was of complex-type for the human (HEK-6E) and non-human mammalian cell lines (CHO-
109 K1, CHO-S) as well as for plant (*Nicotiana benthamiana*)-derived RBD. We found paucimannosidic N-
110 glycosylation for the *Trichoplusia ni* insect cell line (*Tnms42*)-derived RBD (**Fig. S1A, B**). Peptide mapping
111 verified the integrity of the protein primary structure (data not shown). Unoptimized and small-scale
112 electroporation of non-human (CHO-K1 and CHO-S) and baculovirus infection of insect (*Tnms42*) cell lines
113 produced overall yields after purification of less than one mg RBD per liter of culture. Polyethylenimine
114 (PEI) transfection of HEK cells readily provided higher overall volumetric yields (~40 mg/L) without further
115 process optimization (**Fig. 1A, left panel**). Analytical size-exclusion chromatography (HP-SEC) revealed
116 expression platform and production batch-dependent RBD homodimer contents. (**Fig. S2**). For plant-
117 expressed RBD, dimerization was particularly pronounced. We identified an unpaired cysteine residue
118 (Cys538) close to the C-terminus of the canonical RBD sequence as a possible cause for RBD dimerization.
119 A truncated RBD construct (tRBD) lacking this cysteine residue was less prone to homodimer formation,
120 but retained full functionality in the binding assay and similar expression yields (**Fig. 1A, Fig. S3**). From a
121 manufacturing perspective, tRBD thus provided less batch-to-batch variation, which is a pre-requisite for
122 a diagnostic antigen.

123 To assess the performance of the antigens for discrimination between sera from SARS-CoV-2-exposed
124 (n=124) and uninfected individuals (n=210), we applied a high-throughput (HTP) automated bead-based
125 multiplex assay (**Fig. 1B, C**). The performance of diagnostic tests are commonly assessed through receiver
126 operating characteristic (ROC) curves and the analysis of area under the ROC curve (AUC-ROC). ROC curves
127 are simple graphical representations of the relationship between sensitivity and specificity of a test over
128 all possible diagnostic cut-off values and AUCs give the overall ability of a test to discriminate between
129 two populations (5). We used these analyses to assess potential differences in the diagnostic
130 performance of RBD from different expression hosts. Almost all antigens at this high purity demonstrated
131 AUC values of >0.99, demonstrating the high suitability of the RBD from any source as diagnostic antigen.
132 The AUC value of insect-derived RBD was slightly lower (AUC: 0.978 [0.964-0.992]); the differences,
133 however, were not significant (**Fig. 1B**). We then applied antigen-specific cut-offs to compare the
134 performance of the antigens at a pre-defined consensus specificity of 99.1%. At this criterion, we obtained
135 high sensitivities (range 94.4%-96.0%) with all antigens, except for insect-derived RBD. There,
136 seroreactivity with pre-COVID-19 sera was about 2²- (4)-fold higher than observed for CHO-expressed
137 RBDs. This resulted in 26% of COVID-19 sera to fall below the threshold, increasing the rate of false-
138 negatives (**Fig. 1C**). The tRBD displayed a comparable seroreactivity profile to the RBD.

139 During our pre-validation experiments we observed a strong effect of residual host cell proteins on assay
140 performance (**Fig. S4**), even in formulations derived from human cell lines. Therefore, RBD/tRBDs were
141 purified via an Immobilized metal affinity chromatography (IMAC) capture followed by a scalable and fast
142 flow-through Anion exchange (AEX) chromatography step, leading to purities of up to 99%. Owing to
143 reproducible highest production yields of functional protein with adequate diagnostic performance and
144 less batch-to-batch variation, we decided to pursue with HEK-expressed tRBD for our further validations.

145

146 As the NP of SARS-CoV-1 has been described to be well produced in bacteria (6), we decided to produce
147 the SARS-CoV-2 NP in *Escherichia coli*. We combined two recently developed generic manufacturing
148 strategies, the CASPON (cpCasp2-based platform fusion protein process) technology (7) and the enGenes-
149 X-press technology (8), allowing for high-level soluble expression of heterologous proteins. NP was
150 expressed as a fusion protein with an N-terminally fused CASPON tag that enables affinity purification and
151 can afterwards be efficiently proteolytically removed, thereby generating the authentic N-terminus. High
152 soluble volumetric titers of 3.7 g/L in a growth-decoupled fed-batch production process yielded 730 mg/L
153 NP after purification with a modified CASPON platform process (**Fig. 1A, right panel**). This strategy
154 delivered untagged NP protein at exceptionally high quality (93.6% purity, defined as protein full-length
155 content) after a multi-step-downstream process. The remaining impurities consisted of NP-related
156 fragments and RNA. Host cell protein concentration was 0.9 ng/mg NP and dsDNA concentration was 1
157 $\mu\text{g/mg}$ NP, as determined by De Vos and colleagues (9). NP has an intrinsic propensity to oligomerize and
158 displays very slow dissociation from the antibody (Abcam, ab272852). Therefore, we provide an upper
159 limit for the K_D value, and calculated k_{obs} values as a surrogate kinetic parameter instead (**Fig. 1A, right**
160 **panel, Fig. S3**). The nucleocapsid protein also presented with excellent AUC values of 0.994 (0.988-0.999)
161 and comparable performance to HEK-derived tRBD. While the seroreactivity profile of pre-COVID sera
162 appeared to be more heterogenous against the NP than for tRBD, COVID sera demonstrated a more
163 consistent, robust response against the nucleocapsid protein (**Fig 1B, C, right panel**). This comprehensive
164 set of biotechnological and assay performance characteristics prompted us to pursue ELISA test
165 development with HEK-expressed tRBD and bacterially produced NP.

166 **Assessment of antigen-dependency of false-positive and false-negative results**

167 A set of sera (28-31 convalescence sera from the above tested), that was considered to be particularly
168 challenging since it included 80% of the identified outliers or borderline serum samples, was selected to

169 optimize the conditions for an ELISA with tRBD and NP. At the final conditions (6 $\mu\text{g}/\text{mL}$ coating antigen,
170 1:200 serum dilution) we achieved high sensitivities of 85.7% (Luminex) or 100% (ELISA) at the pre-defined
171 consensus specificity criteria (99.1%, Luminex, 92.9% ELISA, **Fig. 2A**) with both antigens. Our findings from
172 the Luminex antigen pre-validations were in good agreement with the ELISA results, as was demonstrated
173 by the excellent cross-platform correlation of the seroreactivity readouts (tRBD: $r_s=0.97$, $p<0.0001$; NP:
174 $r_s=0.87$, $p <0.0001$). Next, we aimed to assess whether false-positive or false-negative results are
175 independent of the test antigen. With both test formats, up to 50% of the false-negative samples did not
176 simultaneously react with both antigens (**Fig. 2B**). Concurrently, none of the false-positive sera in the
177 ELISA, and only 20% of the false-positive sera (5 out of 25) in the Luminex test simultaneously reacted
178 with both the tRBD and NP (**Fig. 2C**). Levels of tRBD- and NP-specific antibodies correlated well with each
179 other ($r_s=0.75-0.80$, $p<0.0001$, **Fig. 2B**) and also with the ability of the respective sera to neutralize
180 authentic SARS-CoV-2 virus. Yet, with partial correlation analysis we could demonstrate that only anti-
181 tRBD antibodies do have a causal relation with viral neutralization ($r_s=0.68$, $p=0.0003$, **Fig. 2D**).

182 **Cut-off modeling and diagnostic performance of the tests in a large validation cohort**

183 The above data provided an indication that reactivity of COVID-19 sera is dependent on the test antigen,
184 fostering the idea for combined use in applications requiring high specificity. Test kits for both antigens
185 were generated (termed Technozym NP or RBD IgG Test, Technoclone, Vienna, AT), providing the antigens
186 in lyophilized form at a coating concentration of $6\mu\text{g}/\text{mL}$. The kits included a five-point calibrator set,
187 based on the RBD-specific antibody CR3022, to enable quantitative readouts and further expand the tests'
188 application fields.

189 Both the tRBD and the NP ELISA were evaluated using 244 samples from patients with active or previous
190 SARS-CoV-2 infection covering the full spectrum of disease presentations (asymptomatic to individuals
191 requiring intensive care). The large specificity cohort ($n=1,126$) covered a great variety in samples from

192 pre-COVID times including sera from individuals with rheumatic disease, human coronavirus infections
193 drawn during winter months to increase the likelihood for respiratory infections. A detailed description
194 of the SARS-CoV-2 positive cohorts can be found in **Table S1**. In ROC-analysis, both assays presented with
195 excellent areas under the curve (tRBD: 0.976, NP: 0.974, **Fig. 3A, B**). The Youden index was maximal at a
196 cut-off of >2.549 U/mL for tRBD (Youden index=0.901) and at >3.010 U/mL for NP (Youden index=0.882)
197 yielding high sensitivities (tRBD: 95.8% [91.6-97.4], NP: 93.0% [89.1-95.9] at these cut-offs. Yet,
198 specificities (tRBD 95.3% [93.6-96.2], NP 95.1% [93.7-96.3]) were insufficient to yield satisfactory positive
199 predictive values (PPVs), which give the probabilities that an individual with a positive test result indeed
200 has antibodies for SARS-CoV-2. At a low seroprevalence rate of 5% the PPVs at these cut-offs would be
201 equivalent to a coin toss, with 50.2% (43.8-56.5) for tRBD and 50.1% (43.6-56.5) for NP. To increase assay
202 specificity of each test individually, thereby increasing predictability at low seroprevalences, cut-off
203 criteria based on the 99th percentile method were established. Ninety-nine percent of all negative samples
204 showed results below 7.351 (95% CI: 5.733-10.900) U/mL for the tRBD and 7.748 (5.304-11.157) U/mL for
205 the NP ELISA. When shifting the cut-off to 8.000 U/mL (taking a safety margin into account), specificities
206 increased to 99.2% for the tRBD and 99.1% for the NP ELISA. At the same time, sensitivities slightly
207 dropped to 86.3% and 76.7% for the tRBD and NP assays, respectively. The PPVs increased to 84.8% for
208 tRBD and 82.5% for NP (**Fig. 3A, B**). To monitor of immune responses after infection or vaccination, a cut-
209 off yielding higher sensitivities at acceptable specificities was established. A cut-off between the criteria
210 suggested by the ROC analysis and that calculated by the 99th percentile method, e.g., 5.000 U/mL, yielded
211 a sensitivity of 89.8% and a specificity of 98.0% for the tRBD assay, as well as a sensitivity of 86.5% and a
212 specificity of 98.3% for the NP assay (**Fig. 3A, B**).

213

214 **Orthogonal testing approach at very low seroprevalences to approximate 100% specificity**

215 For low seroprevalences, when specificities need to approximate 100% in order to achieve acceptable
216 PPVs, we considered an orthogonal testing approach (OTA). Our previous experiments already provided
217 an indication that false-positives among pre-COVID-19 sera do not necessarily react with both antigens
218 (**Fig. 2C**). As a classical OTA might negatively affect sensitivities an adaptive, sensitivity-improved (SI-OTA)
219 was applied (10). To this end, the above-described validation cohorts were screened with the tRBD ELISA.
220 All samples with results ranging between the cut-off defined by the Youden index (taking a safety margin
221 of, *i.e.*, 3.000 U/mL into account) and 35.000 U/mL (as no false-positives occurred above 31.500 U/mL)
222 were re-tested with the NP ELISA. There, also the Youden index criterion, adding a safety margin, was
223 applied for positivity (>3.500 U/mL). Samples with <3.000 U/mL in the screening test were considered
224 negative; samples with results between 3.000 U/mL and 35.000 U/mL in the screening tests and at the
225 same time >3.500 U/mL in the confirmation test were considered positive; samples >35.000 U/mL in the
226 screening test were considered positive. Applying these criterions 133 of 1,370 samples needed to be re-
227 tested. In turn, this approach led to a significantly enhanced specificity (99.8% [99.4-100.0]) when
228 compared to the tRBD test alone both at a cut-off of 5.000 U/mL (+0.019, $P < 0.0001$) and 8.000 U/mL
229 (+0.006, $P = 0.035$). Compared to the latter, sensitivity (88.1% [83.4-91.9]) was improved (+0.037, $p < 0.050$)
230 and the PPV rose to 96.3% (86.7-99.1), see **Fig. 3C**. To achieve this improvement, only 133 (*i.e.*, those with
231 tRBD levels between 3.000 and 35.000 U/mL) of the overall 1,370 samples needed to be re-tested by the
232 NP assay, resulting in less than 10% increase in testing volume.

233 **Cross-reactivity of SARS-CoV-2 IgG antibodies with endemic and seasonal coronaviruses**

234 To better characterize our specificity cohorts, we explored the prevalence of antibodies towards common
235 cold coronaviruses and possible cross-reactivities with our assays. To do so, outliers among the pre-
236 COVID-19 cohort were defined as sera with readouts higher than the 75th percentile + 1.5x interquartile

237 range (IQR) of the total cohort seroreactivity towards the SARS-CoV-2 NP or tRBD (outlier NP: n=17; tRBD:
238 n=4). Above these cutoffs, all sera from our specificity cohorts reacted strongly with the spike proteins of
239 circulating human coronaviruses (hCoVs) HKU-1, OC43, 229E, and NL63, confirming widespread
240 seroprevalence in the general population (**Fig. 4A, B**). To further characterize the identified outliers among
241 the pre-COVID-19 sera, we calculated their relative IgG signals, set them in relation to a roughly equal
242 number of sera located at the other extreme on the seroreactivity scale (sera with readouts <25th
243 percentile toward the respective antigen) and compared the differences in relative IgG levels to that
244 towards hCoV antigens. Among our pre-validation cohort, sera with highest relative reactivity towards NP
245 (mean difference: 0.88, $p>0.0001$) also demonstrated significantly elevated relative median IgG levels
246 towards the spike protein of HKU-1 (mean difference: 0.13, $p=0.0113$, **Fig. 4B**). The specificity cohort we
247 used for clinical validation included 8 sera from individuals with PCR-confirmed hCoV infection. None of
248 these yielded false-positive readouts at a cutoff of 5.000 U/mL (**Fig. 4C**) at comparably low specificities of
249 95.3% (tRBD) and 96.1% (NP) (see **Fig. 3A, B**).

250 **Clinical evaluation of test performance after symptom onset**

251 Diagnostic accuracy of the Technozym NP or RBD IgG Tests was evaluated at different time points after
252 symptom onset in plasma from hospitalized individuals (general ward and intensive care unit [ICU]
253 patients) and outpatients. A total of 104 plasma samples were drawn during the acute and early
254 convalescent phase of SARS-CoV-2 infection. NP-specific IgG levels correlated well with tRBD-specific IgG
255 levels, even at levels being below the set threshold for seropositivity (1-5 d: $r_s=0.67$, $p<0.0001$; 6-10 d:
256 0.76, <0.0001 ; 11-15 d: 0.76, 0.0006, **Fig. 5**). The positivity rates increased over time, peaking at 100% 15-
257 22 days after symptom onset in both assays. True positivity rates for the NP ELISA were consistently higher
258 than with the tRBD ELISA at all time points (1-5 d: NP vs tRBD: 14.7% vs 5.9%; 6-10 d: 45.7% vs 34.2%; 11-
259 15 d: 76.5% vs 64.7%, **Fig. 5 and Table S2**). Yet, sera displayed a great heterogeneity in antibody levels

260 throughout the observation period (**Table S2**). None of the false-negative results among the samples were
261 obtained with both assays. Astonishingly, 85.7% of the sera already contained neutralizing antibodies
262 (median titer: 1:24; range 1:4 – 1:128, **Table S2**) as soon as by day 5 after symptom onset. Of these,
263 however, only a total of 18% of the sera demonstrated seroreactivity above the cut-off for either the NP
264 or tRBD antigen (**Fig. 5**). Yet, the quantitative nature of the assay allowed us to correlate antibody levels
265 below the cut-off for seropositivity and we could demonstrate excellent correlation of tRBD-specific
266 antibodies with neutralizing function at all four investigated time points (1-5 d: $r_s=0.49$, $p=0.0004$; 6-10 d:
267 0.77 , <0.0001 ; 11-15 d: 0.82 , <0.0001 ; 16-22: 0.67 , 0.0003 , **Fig. 5**).

268 **3. Discussion**

269 Superb assay specificity is of utmost importance for the assessment of antibodies directed against SARS-
270 CoV-2, as a substantial proportion of infected individuals escapes identification due to the frequent
271 asymptomatic course of the disease, thereby distorting the true humoral seroprevalence in any given
272 population (11). The biological basis for false-positives is multifactorial, but the influence of the
273 production platform and process-related peculiarities or impurities on protein performance are factors
274 that are often underestimated. While the viral NP is almost always produced in bacteria (12, 13), we
275 expressed the spike receptor binding domain in HEK cells, CHO cells, insect cells and plants (4, 14–16). To
276 find out which of these systems leads to the highest quality and manufacturability of the RBD diagnostic
277 antigen of potentially high demand, we evaluated these production platforms and pre-validated the
278 proteins based on diagnostic performance with a large set of pre-COVID-19 and COVID-19 sera using the
279 Luminex platform. All five expression platforms demonstrated suitability for the production of functional
280 protein, proven by a binding assay with the SARS-CoV-2-RBD-specific mAb CR3022. Yet, in part due to the
281 different transfection methods used, RBD yields from CHO-K1, CHO-S as well as from *Tnms42* insect cells
282 and tobacco plants were insufficient for sustainable commercial antigen production (< 1mg/L, **Fig. 1**). In
283 contrast, HEK cells readily produced overall yields of 40 mg/L using PEI-transfection. Yields of 30 mg/mL
284 per liter have also been described for CHO-expressed RBD. However, this can be traced back to optimized
285 design of expression constructs and improved production processes for stable RBD-expressing CHO cells
286 together with less extensive purification protocols (17). We observed higher basal seroreactivity of control
287 sera with insect-derived RBD than with RBD from human and non-human mammalian cell lines; which is
288 in line with other reports (4). Host-related impurities do not account for that, as insect-cell produced RBD
289 demonstrated the highest purity among all our RBD samples (99%, **Fig. S2**). While there was a common
290 set of false-positive samples shared by RBD from non-human and human mammalian cell lines as well as
291 plants, false-positives reactive with the insect material were entirely insect-RBD-specific (**Fig. S6**). A

292 possible reason may be platform-specific protein modifications, such as glycosylation, that provide the
293 protein with a unique process-derived signature. Indeed, *T. ni*-derived insect cells were demonstrated to
294 generate core α 1,3-fucose structures with allergenic potential in humans (18), which might be associated
295 with this peculiar seroreactivity profile.

296 Based on our observation that RBD tends to form homodimers in an unpredictable manner among
297 different production batches of the same expression host, we used an optimized, truncated version of an
298 RBD as diagnostic antigen -tRBD-, enabling the production of large amounts of RBD with consistent quality
299 (**Fig. S2**). For tRBD performance, antigen purity was of utmost importance, even when expressed in human
300 cell lines. At a consensus specificity of 99.1%, a reduction in tRBD purity by 10% (pure: 97.5%, impure:
301 87.5% purity) resulted in a drastic reduction in sensitivity by 83.9% (pure: 95.2% versus impure: 11.3%,
302 respectively) in the Luminex pre-validation assays (**Fig. S4**). Since purity after an IMAC capture step was
303 highly batch-dependent and resulted in inconsistent seroreactivity profiles, our standard downstream
304 process included a scalable AIEX chromatography polishing step to account for these inconsistencies and
305 to improve the diagnostic performance of the antigens.

306 The two test antigens, tRBD from HEK cells and NP from *E. coli*, were further used for ELISA assay
307 development. We configured the assays with a number of sera taken from SARS-CoV-2-infected
308 individuals with weak antibody responses to ensure high assay sensitivity. In contrast to available
309 literature, we used high antigen coating concentrations (6 μ g/mL) to yield satisfactory readouts (4, 19, 20)
310 and to achieve a high dynamic measurement range. A caveat of many assay validation studies is that
311 performance characteristics are skewed by the exclusive inclusion of samples from hospitalized
312 individuals, where robust antibody levels are to be expected (21). Likewise, the sole consideration of
313 healthy donors in control groups may lead to overestimated assay specificity, as the impact of potential
314 cross-reactive factors present in the general population is largely ignored. In this respect, auto-antibodies
315 commonly found in individuals with inflammatory diseases (22) were already described to cross-react with

316 SARS-CoV-1 antigens (23). To challenge our tests systems, we biased our large specificity cohort (n=1,126)
317 by including samples with an increased propensity for cross-reactivity, including sera from individuals with
318 inflammatory illnesses (n=359), sera from PCR-confirmed hCoV infections (n=8) and sera drawn during
319 winter months to increase the likelihood of respiratory infections (n=494). Similarly, our sensitivity cohort
320 (n=244) included convalescent sera from SARS-CoV-2-infected individuals covering the full spectrum of
321 clinical manifestations (from asymptomatic to ICU patients). Among them 21% of the sera were collected
322 from asymptomatic individuals or from individuals with mild to moderate illness, who may mount less
323 robust and durable antibody responses after an infection (24). Based on these cohorts, we defined
324 adequate test parameters to enable highly specific detection of SARS-CoV-2-specific antibodies. A cutoff
325 deduced by the 99th percentile method (8.000 U/mL) allowed for high specific serodiagnosis with 99.2%
326 for the Technozym RBD Test and 99.1% for the Technozym NP Test (at sensitivities of 86.3% and 76.7%,
327 respectively). This is a remarkable result for a tetramethylbenzidine-based manual test system,
328 considering the highly diverse nature of our study cohorts. While some automated systems were
329 described to achieve specificities approximating 100% (25, 26), assay performance is highly cohort-
330 specific. The use of diverse study cohorts was also associated with performance deteriorations in such
331 test platforms (i.e. Abbot, Specificity: 97.5%)(27). For the Meduni Wien Biobank cohort we had
332 performance data with CE-marked automated test systems available (10) to directly compare with our
333 ELISAs at the high specificity cut-off criterion (8.000 U/mL). With an AUC of 0.987 [0.979-0.992] and a
334 specificity of 99.1%, the NP ELISA presented with comparable performance to the Abbott SARS-CoV-2
335 chemiluminescence microparticle assay (AUC: 0.993 [0.987-0.997], **Fig. S5**, Sp 99.2%) (10), that also relies
336 on the NP antigen. The tRBD ELISA even outperformed the DiaSorin LIAISON® SARS-CoV-2 S1/S2 IgG
337 chemiluminescence assay (tRBD ELISA: AUC/Sp/Sen=0.993/99.2%/84.9% vs DiaSorin:0.976/98.2%/82.8%,
338 see **Fig. S5** and Perkmann *et al* (10). While we cannot rule out minor cross-reactivity between hCoV-

339 specific antibodies and SARS-CoV-2 antigens, they appeared to have a limited effect on assay
340 performances (**Fig. 4C**).

341 Yet, for an estimated seroprevalence of 5% in the general European population (28, 29), a test with a
342 specificity and sensitivity of 99.2% and 86.3%, respectively, only scores a PPV of 85.0% resulting in 15
343 false-positive results out of 100, which is still insufficient. In line with previous results from us and others
344 (30–32), we demonstrate that false-positive results are largely antigen-dependent (**Fig. 2B, Fig. 4C**).

345 Orthogonal testing is suggested by the Centers of Disease Control and Prevention (CDC) to remedy
346 specificity problems in low transmission settings (33). Previous studies have used RBD as screening antigen
347 and the trimeric spike protein or the spike S2 domain in second-line tests to confirm initial positive results
348 (4, 32). Such conventional orthogonal test strategies, however, increase specificity often at the expense
349 of sensitivity. We therefore established an adaptive orthogonal test algorithm where positive sera were
350 first identified with the tRBD ELISA allowing for highly sensitive testing (at the expense of specificity) and
351 samples within a predefined area of uncertainty then underwent confirmatory testing with the NP ELISA
352 (10). This two-test algorithm resulted in a cumulative specificity of 99.8% and an even higher sensitivity
353 of 88.1% (+0.037, $p < 0.050$), yielded a PPV of 96.3% [86.7-99.1] (**Fig. 3**). This is an excellent result for a
354 manual test format and its specificity is on par with other orthogonal tests relying on automated systems
355 (10).

356 As the Technozym NP and RBD ELISAs provide a five-point calibrator, set ELISA antibody levels can be
357 quantified, compared and followed over time. For such an application, we chose a cut-off of 5.000 U/mL
358 that allowed for more sensitive analysis of antibody levels at acceptable specificity, adapted from the cut-
359 off given by the Youden index. With convalescent sera taken at median 43-54 days post-symptom onset,
360 the tRBD ELISA allowed for a more sensitive detection of antibodies than the NP ELISA (**Fig. 3A, B**). Yet,
361 time-resolved analysis of seroconversion demonstrated that NP-specific antibodies develop earlier after

362 an infection and true positive rates were consistently higher with the NP ELISA for samples collected
363 within the first 15 days post-symptom onset (**Fig. 5, Table S2**). This phenomenon has already been
364 described in patients infected with SARS-CoV-1(34, 35) and was associated with higher sensitivities of
365 other SARS-CoV-2 test systems, relying on the NP, in the early phase after an infection (36). Determining
366 the neutralizing capacity of SARS-CoV-2 anti-RBD antibodies is critical to elucidate possible protective
367 effects of the immune response. Considering all neutralizing activity above background as positive, we
368 observed neutralizing antibodies in 85% of the sera already by day five after symptom onset (**Fig. 5**), which
369 is in line with previous studies (37, 38). Of note, RBD-seroconversion, defined by antibody levels above a
370 threshold of 5.000 U/mL, was observed for only 6% of the sera at this time point. Yet, despite 33 out of
371 35 samples demonstrating reactivity below our pre-defined cutoff, neutralizing titers correlated well with
372 RBD-specific IgG responses. A recent study demonstrated that the early neutralizing response is
373 dominated by RBD-specific IgA antibodies (39). As we exclusively measured RBD-specific IgG responses
374 we cannot rule out that part of the early neutralizing activity we observe derive from neutralizing IgA or
375 even earlier IgM responses.

376 Tests for the screening of reconvalescent COVID-19 patients for the presence of anti-SARS-CoV-2
377 antibodies are of great interest for identifying suitable donors for convalescent plasma therapy (40). A
378 retrospective, propensity score–matched case–control study performed at the Mount Sinai hospital (New
379 York, NY) provides evidence for a survival benefit in patients receiving convalescent plasma transfusion as
380 an effective intervention in COVID-19 (40). In August 2020, the FDA issued a new guidance on the
381 Emergency Use Authorization (EUA) for COVID-19 convalescent plasma, recommending plasma donations
382 to be qualified by either the Mount Sinai COVID-19 ELISA IgG Antibody Test or Ortho VITROS IgG assay
383 (41). Prior to this guidance, NTs of at least 1:160 were considered acceptable in the absence of high-titer
384 samples (42). As we did not have the beforementioned tests available, we qualified plasma donors
385 according to the NT 1:160 criterion. The fraction of samples exceeding this threshold gradually increased

386 over time and by day 15 after symptom onset, 53% of the sera and by day 22, 72% of sera had titers higher
387 than 1:160 (**Fig. 5, Table S2**). The geometric mean RBD titers in these sera corresponded to 159.1 U/mL
388 and 183.7 U/mL, respectively. Since correlates of protection from infection remain to be determined we
389 cannot deduce whether these titers are clinically relevant in prophylaxis, at this point.

390 **4. Discussion**

391 In conclusion, we have developed two highly specific, quantitative, easy-to-implement and now
392 commercially available SARS-CoV-2 antibody tests and defined optimal thresholds for their application in
393 different aspects of clinical use. In addition to their simple format, the two tests are equally well suited as
394 most automated CE-marked systems for high specificity applications, such as seroprevalence studies.
395 Moreover, the RBD ELISA allows for the identification of donors for convalescent plasma therapy as RBD-
396 specific antibody levels correlate well with the induction of functional neutralization responses. Both tests
397 allow to comprehensively monitor the dynamics of antibody responses after infection. Yet, our data
398 disclose different kinetics for antigen-specific antibody responses, which affect their performance at
399 different time points after an infection. These findings are essential for ongoing efforts to establish
400 serological tests for clinical diagnostics. In this respect, also test performance with convalescent sera
401 collected more than 2 months after infection and the effect of antigen-specific antibody waning should
402 be carefully addressed in future studies and compared to the comprehensive findings of this study.

403

404 5. Methods

405 5.1 Production of recombinant SARS-CoV-2 antigens for serodiagnosis

406 5.1.1. Genetic constructs

407 pCAGGS mammalian expression vectors encoding the canonical SARS-CoV-2 receptor-binding domain
408 (RBD, pCAGGS-RBD, aa Arg319 – Phe541, residue numbering as in NCBI Reference sequence:
409 YP_009724390.1) sequence from the first human isolate Wuhan-1 (43) with a C-terminal hexa-histidine
410 tag, were a kind gift from Florian Krammer, Icahn School of Medicine at Mount Sinai, NY (4). Both
411 sequences were codon-optimized for the expression in mammalian cells.

412 A pTT28 mammalian expression vector (National Research Council, NRC, Ottawa, Canada) encoding a
413 truncated version of the SARS-CoV-2 Spike receptor-binding domain (tRBD, pTT28-tRBD, aa Arg319 -
414 Lys537) with a C-terminal octa-histidine tag was generated.

415 A pEAQ-HT plant expression vector (44) encoding RBD (pEAQ-HT-RBD, aa Arg319 – Phe541) fused to the
416 barley α -amylase signal peptide and a C-terminal hexa-histidine tag was generated. The RBD sequence
417 was codon-optimized for the expression in plants and synthesized by GeneArt (Thermo Fisher Scientific,
418 Regensburg, DE).

419 A pET30*acer E. coli* expression vector (8) encoding the full-length SARS-CoV-2 Wuhan-1 NP sequence (aa
420 Met1–Ala419, GenBank: NC_045512.2) (43) fused to a completely removable N-terminal CASPON tag (7,
421 45), yielding pET30*acer*-CASPON-NP, was generated as described elsewhere (9). Briefly, SARS-CoV-2 NP
422 sequence was amplified via PCR using the qPCR positive control plasmid 2019-nCoV_N obtained from
423 Integrated DNA Technologies (Coralville, Iowa, USA) and was fused to the CASPON tag consisting of the
424 negative charged T7AC solubility tag (7), a hexa-histidine tag, a short linker (GSG) and the caspase-2
425 cleavage site (VDVAD) resulting in the sequence MLEDPERNKERKEAELQAQTAEQHHHHHHGSGVDVAD.

426 Expression vectors pFUSEss-CHlg-hG1 and pFUSEss2-CLlg-hK, encoding the heavy and light chains of the
427 SARS-CoV/SARS-CoV-2 monoclonal antibody CR3022 (46) were kindly provided by Florian Krammer (Icahn
428 School of Medicine at Mount Sinai, New York, NY).

429 **5.1.2 Large-scale production of transfection-grade plasmid DNA**

430 Plasmid DNA for transient transfection of HEK293-6E cells was produced according to an upstream process
431 described previously (47). Briefly, the plasmids pCAGGS-RBD and pTT28-tRBD were transformed into *E.*
432 *coli* JM108 by electroporation and cultivated in 1-L fed-batch mode. Cells were harvested by
433 centrifugation and pDNA was extracted by alkaline lysis at 5 g/L cellular dry mass (CDM) following a
434 protocol of Urthaler and colleagues (48). pDNA was processed to >95% purity by multiple chromatography
435 steps based on a platform purification protocol (Cytiva, Little Chalfont, UK)(49).

436 **5.1.3 Transient expression of RBD, tRBD and NP in diverse biotechnological platforms**

437 ***Human embryonic kidney cells***

438 **Shake flask cultivation.** HEK293-6E cells (licensed from National Research Council, NRC, Ottawa, Canada)
439 were routinely cultivated in suspension in Freestyle™ F17 medium supplemented with 4 mM L-glutamine,
440 0.1% (v/v) Pluronic F-68 and 25 µg/mL G-418 (all Thermo Fisher Scientific, Waltham, MA) in a humidified
441 atmosphere of 5-8% (v/v) CO₂ at 37°C shaking at 125 rpm. Polyethylenimine (PEI)-mediated transient
442 transfections with either pCAGGS-RBD, pTT28-tRBD or pFUSEss-CHlg-hG1 and pFUSEss2-CLlg-hK for the
443 expression of RBD, tRBD or mAb CR3022 were performed according to the manufacturer's protocol as
444 previously described (50, 51).

445 Transfections were performed by dropwise addition of a mixture of one µg plasmid DNA and two µg linear
446 25-kDa or 40-kDa PEI (Polysciences, Inc., Hirschberg, DE) per mL of culture volume ($1.7 - 2.0 \times 10^6$
447 cells/mL). Two and four days post-transfection, cells were supplemented with 0.5% (w/v) tryptone N1

448 (Organotechnie, La Courneuve, FR) and 0.25% (w/V) D(+)-glucose (Carl Roth, Karlsruhe, DE). Supernatants
449 were harvested five to six days post-transfection by centrifugation (2000 g, 15 min) and were filtered
450 through 0.45 μ m filters before downstream procedures.

451 **Medium-scale cultivation.** Stepwise upscaling was performed using a Multi-bioreactor system DASGIP
452 (Eppendorf, Hamburg, DE) followed by a 10 liter scale bioreactor System BioFlo320 (Eppendorf, Hamburg,
453 DE). The bioreactors were inoculated at half the final volume (F17 expression medium supplemented with
454 4 mM L-Glutamine and 0.1% Pluronic) with a seeding density of 0.5×10^6 cells/mL. The inoculum was
455 prepared in shake flask cultures as described above. The bioreactors were controlled to a pH of 7.2 using
456 CO₂ and 7.5% (w/V) carbonate base and to 50% (v/v) dissolved oxygen by submerged aeration.
457 Transfection was performed at a cell concentration of 1.7×10^6 . PEI and the respective plasmid DNA were
458 diluted in media mixed and incubated at room temperature for 10 minutes prior to addition to the cultures
459 (45 μ g PEI and 15 μ g of plasmid per 10^6 cells). Twenty four hours post transfection, cells were expanded
460 and 24 hours later were fed a TN1 peptone at a concentration of 0.5% (v/v). Each day post-transfection
461 viability, cell density and glucose concentration were measured and a daily bolus feed to a glucose
462 concentration of 2.5 g/L was performed. The cultures were harvested once viability dropped below 60%.

463 ***Chinese hamster ovary cells***

464 CHO-K1 and CHO-S cells were routinely propagated in CD-CHO medium (Thermo Fisher Scientific,
465 Waltham, MA) or in Hyclone Actipro medium (Cytiva, Chicago, IL) both supplemented with 0.2% (v/v) Anti-
466 Clumping Agent (Thermo Fisher Scientific, Waltham, MA) and 8 mM L-glutamine (CHO-K1, Sigma Aldrich,
467 St. Louis, MO) or 8 mM GlutaMAX (CHO-S, Thermo Fisher Scientific, Waltham, MA), respectively. Cells
468 were cultivated in suspension at 37°C, 7% (v/v) CO₂ and humidified air, shaking at 140 rpm.

469 For nucleofection, a total of 1×10^7 cells in the exponential growth phase were pelleted for 8 min at 170
470 g and were resuspended in 99 μ L resuspension buffer R (Thermo Fisher Scientific, Waltham, MA). Cells

471 were mixed with pCAGGS-RBD, which had been pre-diluted with UltraPure™ DNase/RNase-Free distilled
472 water to a concentration of 2 µg/µL in a total volume of 11 µL and were electroporated with a Neon®
473 Nucleofector using a 100 µL Neon® Transfection Kit (all Thermo Fisher Scientific, Waltham, MA) with 1700
474 V and one pulse of 20 ms. Seven to eight transfections per cell line were performed and subsequently
475 pooled in a 500 mL shake flask with a 200 mL working volume. Supernatants were harvested five days
476 post transfection by centrifugation (170 g, 10 min) and were sterile-filtered before further use.

477 ***Insect cells***

478 *Tnms42*, an alphanodavirus-free subclone of the High-Five insect cell line (52, 53), were routinely
479 propagated in adherent culture in HyClone SFM4 insect cell medium (Cytiva, Marlborough, MA) at 27°C
480 and were expanded in suspension culture for recombinant protein expression. A passage one virus seed
481 stock expressing the SARS CoV-2 RBD was amplified in *Sf9* cells to generate a passage three working stock
482 and was titrated by plaque assay as previously described (54). *Tnms42* insect cells at 2×10^6 cells/mL were
483 infected at a multiplicity of infection (MOI) of two, and the supernatant was harvested three days post-
484 infection, clarified (1,000 g, 10 min, followed by 10,000 g, 30 min) and was filtered through a 0.45 µm
485 filter before downstream procedures.

486 ***Tobacco plants***

487 The pEAQ-HT-RBD expression vector was transformed into *Agrobacterium tumefaciens* strain UIA143 (44).
488 Syringe-mediated agroinfiltration of leaves from five-week-old *Nicotiana benthamiana* ΔXT/FT plants was
489 used for transient expression (55). Four days after infiltration, leaves were harvested and intracellular
490 fluid was collected by low-speed centrifugation as described in detail elsewhere (56).

491

492 ***E. coli***

493 The pET30*acer*-CASPON-NP expression vector was transformed into *E. coli* enGenes-X-press for growth-
494 decoupled recombinant protein production as described elsewhere(8) Briefly, for cultivation cells were
495 grown in fed-batch mode in a 1.0 L (0.5 L batch volume, 0.5 L feed) DASGIP® Parallel Bioreactor System
496 (Eppendorf AG, Hamburg, DE) equipped with standard probes (pH, dissolved oxygen [pDO]). The pH was
497 maintained at 7.0 ± 0.05 , temperature was maintained at $37 \pm 0.5^\circ\text{C}$ during the batch phase and decreased
498 to $30 \pm 0.5^\circ\text{C}$ at the beginning of the feed phase. The dissolved oxygen level was stabilized at $> 30\%$ (V/V).
499 Induction of NP production was facilitated at feed hour 19 with the addition of 0.1 mM IPTG and 100 mM
500 arabinose.

501 **5.1.4. Downstream procedures**

502 **Purification of SARS-CoV-2 RBD and tRBD from different expression systems**

503 His-tagged RBD and tRBD from filtered HEK supernatants, as well as RBD from *Tnms42* insect cell
504 supernatants, were concentrated and diafiltrated against 20 mM sodium phosphate buffer supplemented
505 with 500 mM NaCl and 20 mM imidazole (pH 7.4) using a LabScale TFF system equipped with a Pellicon™
506 XL Ultracel 5 kDa, 0.005 m² ultrafiltration module (Merck, Darmstadt, DE). The proteins were captured
507 using a 5-mL HisTrap FF Crude or a 1-mL HisTrap Excel immobilized metal affinity chromatography (IMAC)
508 column connected to an ÄKTA Pure chromatography system (all from Cytiva, Marlborough, MA) and were
509 eluted by applying a linear gradient of 20 to 500 mM imidazole over 5 to 20 column volumes, as
510 appropriate. Intracellular fluid collected from plant material was directly loaded onto a 5-mL HisTrap HP
511 column and was purified as described elsewhere (57). CHO-K1 and CHO-S expression supernatants were
512 supplemented with 20 mM imidazole and were directly loaded onto a 1-mL HisTrap FF column connected
513 to an ÄKTA Start chromatography system (both Cytiva, Marlborough, MA), equilibrated with 50 mM

514 sodium phosphate buffer supplemented with 300 mM NaCl and 20 mM imidazole (pH 7.4). Proteins were
515 eluted by applying a linear gradient of 20 to 500 mM imidazole over 20 column volumes.

516 Fractions containing RBD or tRBD were pooled and either diluted with 20 mM sodium phosphate buffer
517 (pH 7.4) to a conductivity of ~10 mS/cm and then loaded onto a Fractogel EMD DEAE column (Merck
518 Millipore, Germany) or loaded onto HiTrap DEAE FF column (Cytiva, Marlborough, MA), both pre-
519 equilibrated with 20 mM sodium phosphate buffer (pH 7.4). A residence time of 2 minutes was used. The
520 flow-through fractions, containing RBD or tRBD, were collected. Impurities were subsequently eluted
521 using 20 mM sodium phosphate buffer, 1 M NaCl, pH 7.4 and the column was cleaned in place by
522 incubation in 0.5 M NaOH for 30 minutes. The protein of interest present in the flow-through fraction was
523 buffer-exchanged into PBS using Amicon Ultra-15 Ultracel 10 kDa spin columns (Merck Millipore,
524 Germany) or was dialyzed against PBS. IMAC-captured RBD from insect cell supernatants was ultra-
525 and diafiltrated using Amicon Ultra Centrifugal Filter Units (10 kDa MWCO, Merck Millipore) to change
526 the buffer to PBS and was further purified by size exclusion chromatography using a HiLoad 16/600
527 Superdex 200 pg column (Cytiva, Marlborough, MA) equilibrated with the same buffer. Fractions
528 containing RBD were concentrated using Amicon Ultra-15 Ultracel 10 kDa spin columns (Merck Millipore,
529 Germany). All purified proteins were quantified by measuring their absorbance at A_{280} with a Nanodrop
530 instrument and stored at -80°C until further use.

531 **Purification of SARS-CoV-2 NP from *E. coli* cellular lysates**

532 The purification of NP was optimized and performed as described by De Vos and colleagues (9). In brief,
533 NP was produced by using the CASPON platform process(45) with modifications. The process consisted of
534 an IMAC capture step (WorkBeads 40 Ni NTA, Bio-Works, Uppsala, SE) of the clarified cell lysate. A
535 nuclease treatment (Salt Active Nuclease High Quality, ArcticZymes Technologies ASA, Tromsø, NO) was
536 required to reduce CASPON-NP nucleic acid binding. Imidazole was removed from the IMAC eluate using

537 a Butyl Sepharose HP hydrophobic interaction chromatography (Cytiva, Uppsala, SE) which also separated
538 full-length from fragmented CASPON-NP. A variant of cpCasp2 (7) was used to remove the affinity fusion-
539 tag. Finally, an IMAC polishing step was used to separate native NP from residual CASPON-NP, the free
540 affinity fusion-tag, the affinity-tagged cpCasp2 variant and metal binding host cell proteins. The polishing
541 fraction was buffer exchanged to PBS using tangential flow filtration on Pellicon 3 Ultracel 10 kDa
542 membrane (Merck Millipore, Darmstadt, DE).

543 **Purification of mAb CR3022**

544 mAb CR3022 was purified by affinity chromatography using a 5-mL HiTrap Protein A HP column connected
545 to an ÄKTA pure chromatography system (both from Cytiva, Marlborough, MA) according to the
546 manufacturer's protocol. The antibody was eluted using 0.1 M glycine-HCl buffer (pH 3.5). Eluate fractions
547 containing CR3022 were immediately neutralized using 1 M Tris-HCl buffer (pH 8.0), pooled and
548 concentrated using Amicon ultrafiltration cartridges with a cut-off of 10 kDa (Merck, Darmstadt, DE) and
549 were further dialyzed against PBS (pH 7.4) at 4°C overnight using SnakeSkin Dialysis Tubing with a 10 kDa
550 cut-off (Thermo Fisher Scientific, Germering, DE). CR3022 was further purified by size exclusion
551 chromatography using a HiLoad 16/600 Superdex 200 pg column (Cytiva, Marlborough, MA) equilibrated
552 with the same buffer as used for dialysis.

553 **5.2 Commercial antigen and antibody reagents**

554 Recombinant spike proteins of the four common cold hCoV strains, HKU-1, OC43, NL63 and 229E were
555 purchased from Sino Biological Inc, Beijing, CN (#40606-V08B, #40607-V08B, #40604-V08B and #40605-
556 V08B, respectively). A recombinant chimeric human/mouse anti-SARS-CoV-2 NP antibody consisting of a
557 mouse scFv fused to the Fc region of human IgG1 (clone 1A6) was purchased from Abcam, Cambridge, UK
558 (#ab272852).

559

560 **5.3 Assessment of recombinant protein quality**

561 **5.3.1 Analytical size exclusion chromatography (SEC)**

562 High-performance liquid chromatography (HP)-SEC experiments were performed on a Dionex™
563 UltiMate™ 3000 RSLC system equipped with an LPG-3400SD Standard Quaternary Pump module, a WPS-
564 3000 TSL Analytical Split-Loop Well Plate Autosampler and a DAD-3000 Diode Array Detector equipped
565 with a ten µL analytical flow cell (all from Thermo Fisher Scientific, Germering, DE). RBD, tRBD and NP
566 samples (25-80 µg per sample) were run on a Superdex™ 200 Increase 10/300 GL column (Cytiva, Uppsala,
567 SE) and UV signals were detected at $\lambda = 280$ nm. For RBD and tRBD, Dulbecco's PBS buffer (DPBS)
568 supplemented with 200 mM NaCl was used as mobile phase, the flow rate was set to 0.75 mL/min and a
569 45 min isocratic elution was performed. For NP samples 0.1 M sodium phosphate buffer (pH 7.0)
570 containing 300 mM NaCl was used as mobile phase, the flow rate was set to 0.5 mL/min and a 60 min
571 isocratic elution was performed. HP control, data acquisition and data evaluation were performed using
572 Chromeleon™ 7.2 Chromatography Data System software (Thermo Fisher Scientific, Germering, DE).
573 Sample purity (P), monomer (M), dimer (D) and full-length (FL) content were determined based on the
574 respective peak area of the UV signal at 280 nm. For RBD and tRBD purity was defined as $P=(M+D)/\text{total}$
575 area, monomer and dimer content were respectively defined as $M[\%]=M/(M+D)*100$ and $D=100-M[\%]$.
576 For NP, full-length content was defined as $FL[\%]=FL/\text{total area}$.

577 **5.3.2 Bio-Layer Interferometry (BLI) measurements**

578 Interaction studies of RBD, tRBD and NP with in-house produced anti-RBD mAb CR3022 and a commercial
579 anti-SARS-CoV-2 nucleocapsid protein antibody (ab272852, Abcam, Cambridge, UK) were performed on
580 an Octet RED96e system using high precision streptavidin (SAX) biosensors (both from FortéBio, Fremont,
581 CA). Antibodies were biotinylated using the EZ-Link Sulfo-NHS-LC-Biotin kit (Thermo Fisher Scientific,
582 Waltham, MA). Excess sulfo-NHS-LC-biotin was quenched by adding Tris-HCl buffer (800 mM, pH 7.4) to a

583 final concentration of 3 mM. Biotinylated antibodies were further purified using PD-10 desalting columns
584 (Cytiva, Marlborough, MA) according to the manufacturer's protocol. All binding assays were conducted
585 in PBS supplemented with 0.05% (v/v) Tween 20 and 0.1% (w/v) BSA (PBST-BSA) at 25°C with the plate
586 shaking at 1,000 rpm. SAX biosensors were first equilibrated in PBST-BSA and then loaded with the
587 respective biotinylated capture molecules, either for 180 sec (34 nM CR3022 solution) or until a signal
588 threshold of 0.8 nm was reached (50 nM anti-NP mAb solution). Subsequently, antibody-loaded
589 biosensors were dipped into PBST-BSA for 90 sec to record a baseline, before they were submerged into
590 different concentrations of their respective analytes. To determine K_D values, biotinylated antibodies
591 loaded onto biosensors were exposed to six concentrations of the binding partners (RBD, tRBD or NP) to
592 cover a broad concentration range around the respective K_D value (58). For antigen association, mAb
593 CR3022 was exposed to a three-fold serial dilution of RBD or tRBD (range: 300 nM - 1.2 nM in PBST-BSA)
594 for 300 sec, while anti-NP mAb was dipped into two-fold serial dilutions of the NP protein (40 nM - 1.3
595 nM in PBST-BSA) for 600 sec. For dissociation, the biosensors were dipped into PBST-BSA. Each experiment
596 included a baseline measurement using PBST-BSA (negative control) as well as a positive control (RBD
597 monomer) where applicable. SAX biosensors loaded with biotinylated CR3022 or anti-NP mAb could be
598 regenerated by dipping them into 100 mM glycine buffer (pH 2.5). RBD or tRBD proteins were measured
599 in triplicates or quadruplicates, while NP proteins were measured in duplicates. No unspecific binding of
600 proteins to SAX biosensors was observed. Data were evaluated under consideration of the lower limit of
601 detection (LLOD) and lower limit of quantification (LLOQ) as reported elsewhere (59, 60). The analysis was
602 performed using the Octet data analysis software version 11.1.1.39 (FortéBio, Fremont, CA) according to
603 the manufacturer's guidelines. For easier comparison of the RBD variants produced in different expression
604 hosts, the K_D values were determined from the measured equilibrium response (steady state analysis).
605 However, the interaction between the CR3022 mAb and the final tRBD batches were also evaluated
606 kinetically by fitting the BLI data to a 2:1 heterogeneous ligand binding model. Note, although the CR3022

607 mAb has two identical binding sites, the second binding event is dependent on the first binding since
608 allosteric effects or sterical hindrance can ultimately lead to a positive or negative cooperative binding
609 behavior (51, 61, 62). However, in case of the reported interaction, the affinity constant (K_D) values are
610 very close to one other in the low nanomolar range.

611 The interaction between the NP protein and the anti-NP mAb is difficult to characterize due to avidity
612 effects that arise from the dimeric nature of both interaction partners. Kinetic evaluation of the BLI data
613 is problematic since the dissociation curves are heterogenic. Additionally, if the dissociation phase shows
614 less than 5% decrease in signal during the defined dissociation phase, as observed for the lower
615 concentration range of NP protein, a precise determination of the dissociation rate constants (k_d) is not
616 possible (63, 64). However, it is feasible to calculate an upper limit for the k_d (s^{-1}) which is given by
617 $k_d < -\ln(0.95)/t_d$, where t_d is the dissociation time in seconds (63, 65) Thus, an upper limit for the K_D value,
618 calculated by the ratio of k_d/k_a , resulted in < 0.7 nM, suggesting a strong interaction in the picomolar
619 range. Moreover, for comparison of single batches the observed binding rate (k_{obs}) was plotted as a
620 function of the NP concentration and used for the comparison of the single batches.

621

622 **5.3.3 Liquid Chromatography Electrospray Ionization Mass Spectrometry (LC/ESI-MS)**

623 Purified proteins were S-alkylated with iodoacetamide and digested with endoproteinases LysC (Roche,
624 Basel, CH) and GluC (Promega, Madison, WI) or chymotrypsin (Roche, Basel, CH) in solution. Digested
625 samples were analyzed using a Thermo Ultimate 3000 HP connected to a 150 x 0.32 mm, 5 μ m BioBasic
626 C18 column (both Thermo Fisher Scientific, Waltham, MA) and a maXis 4G QTOF mass spectrometer
627 (Bruker, Billerica, MA). An 80 mM ammonium formate buffer was used as the aqueous solvent and a linear
628 gradient from 5% B (B: 80% acetonitrile) to 40% B in 45 min at a flow rate of 6 μ L/min was applied, followed
629 by a 15 min gradient from 40% B to 95% B that facilitated elution of large peptides. The MS system was
630 equipped with the standard ESI source and operated in positive ion, DDA mode (= switching to MSMS

631 mode for eluting peaks). MS-scans were recorded (range: 150-2,200 Da) and the six highest peaks were
632 selected for fragmentation. Instrument calibration was performed using ESI calibration mixture (Agilent,
633 Santa Clara, CA). The analysis files were converted (using Data Analysis, Bruker) to mgf files, which are
634 suitable for performing a MS/MS ion search with MASCOT. The files were searched against a database
635 containing the target sequences. In addition, manual glycopeptide searches were done. Glycopeptides
636 were identified as sets of peaks consisting of the peptide moiety and the attached N-glycan varying in the
637 number of HexNAc, hexose, deoxyhexose and pentose residues. Theoretical masses of these peptides
638 were determined using the monoisotopic masses for the respective amino acids and monosaccharides.

639 **5.4 Ethics statement**

640 The present study includes work with human sera from three different sites. Acute lithium heparin plasma
641 samples collected from outpatient and hospitalized individuals for routine clinical testing were available
642 at the B&S Central Laboratory Linz, Austria. Left-over samples were assessed for SARS-CoV-2 antibody
643 levels and neutralizing titers in the early phase of infection and the study protocol was approved by the
644 ethics committee of Upper Austria (EK1083/2020), in accordance with the Declaration of Helsinki. For
645 ELISA validations, left-over sera from SARS-CoV-2 patients and sera from convalescent donors, as well as
646 historical sera (<2020) were taken from the MedUni Wien Biobank, as approved by the ethics committee
647 of the Medical University of Vienna (EK 1424/2020). The underlying sample collections were reviewed and
648 approved by the ethics committee of the Medical University of Vienna (EK 595/2005, EK 404/2011, EK
649 518/2011), or by the ethics committee of the City of Vienna (EK-11-117-0711), respectively. Samples from
650 hospitalized COVID-19 patients at the University Hospital of Innsbruck, reconvalescent COVID-19 patients
651 with persistent cardio-pulmonary damage participating in a prospective observational study (CovILD-
652 study, ClinicalTrials.gov number, NCT04416100, Reference: PMID: 33303539) and reconvalescent persons
653 volunteering as plasma donors were used for test validation in Innsbruck (66). The underlying sample

654 collections were reviewed and approved by the ethics committee of the Medical University of Innsbruck
655 (EK 1103/2020, EK 1167/2020). Left-over SARS-CoV-2 acute and convalescent sera from blood donors and
656 pre-COVID-19 sera from the Austrian Institute of Technology were taken for SARS-CoV-2 antigen pre-
657 validation and the study was approved by the ethics committee of the city of Vienna (EK 20-179-0820).

658 **5.5 Human serum and plasma samples**

659 **5.5.1 Sensitivity cohorts**

660 **SARS-CoV-2 acute sera from a cohort of outpatient and hospitalized individuals, B&S Central Laboratory**

661 **Linz, Austria**

662 A cohort of hospitalized individuals and outpatients included a total number of 64 SARS-CoV-2 RT-PCR-
663 confirmed (from respiratory specimens) COVID-19 patients (median age 65 [14-95, IQR 56-87 years],
664 17.2% females) who were treated in one of the two tertiary care hospitals Konventhospital Barmherzige
665 Brueder Linz or Ordensklinikum Linz Barmherzige Schwestern in Linz, Austria, between March 15th – April
666 10th 2020. Of these, ten patients were treated as outpatients and 54 patients were hospitalized; twelve of
667 them were treated at the intensive care unit (ICU). From the 64 patients, a total of 104 serial blood
668 samples were drawn at different time points after symptom onset until April 10th, 2020. Sixty-four patients
669 had at least one, 28 patients had two, nine patients had three and three patients had four blood draws,
670 which were sent to the central laboratory for routine clinical testing. The date of onset of symptoms was
671 retrieved from medical records and was available for all patients. Left-over lithium heparin plasma
672 samples were aliquoted and frozen at -80°C and had up to two freeze-thaw cycles.

673 **Sera of SARS-CoV-2-positive patients and convalescent donors, Medical University of Vienna and** 674 **Medical University of Innsbruck**

675 The SARS-CoV-2 positive samples for ELISA validation comprise 70 serum specimens from unique patients
676 or convalescent donors with (previous) SARS-CoV-2 infection from Vienna (either PCR-positive or

677 symptomatic close contacts), as well as 174 SARS-CoV-2 PCR positive patients including hospitalized
678 patients (n=123) and convalescent blood donors (n=51) from Innsbruck. All samples were collected >14
679 days after symptom onset (or positive PCR, in case of asymptomatic infection). A representative serum
680 panel of these samples (n=28-31) was taken for the pre-validation of SARS-CoV-2 antigens by ELISA and
681 for the assessment of SARS-CoV-2 neutralization titers.

682 **SARS-CoV-2-convalescent and acute sera from a cohort of non-hospitalized blood donors, Austrian** 683 **Institute of Technology (AIT) and Medical University of Vienna**

684 The sensitivity cohort for antigen pre-validation covered 124 COVID sera. Among these, 96 sera were
685 deidentified excess samples from infected individuals collected for routine SARS-CoV-2 serodiagnosis
686 using a seven-plex bead-based Luminex-FlexMap system-based serotest and were available at the AIT.
687 These serotests had been conducted similar to the analysis procedure outlined below. Seronegativity
688 and/or seropositivity was based on cut-off values and end-point titers defined according to Frey *et al* (67)
689 on the basis of 160 pre-COVID-19 sera. Additionally, the study cohort included a set of 28 COVID-19 sera
690 from the Medical University (from the above), covering samples from primarily asymptomatic individuals
691 or those with mild to moderate illness.

692 **5.5.2 Specificity cohorts**

693 **Pre-COVID-19 cohort, MedUni Wien Biobank**

694 The pre-COVID-19 cohort covered a total of 1,126 samples from healthy, non-SARS-CoV-2-infected
695 individuals collected before 2020 to guarantee seronegativity. Banked human samples including sera from
696 voluntary donors (n=265, median age 38 [25-52] years, 59.0% females), samples from a large population-
697 based cohort aged 8-80 years, representing a cross-section of the Austrian population (N=494, collected
698 2012-2016 from November to March to increase the likelihood of infection with other respiratory viruses,
699 median age 43 [26-56], 50.0% females)(68), samples from patients with rheumatic diseases (N=359,

700 median age 52 [41-61], 76.0% females), and eight samples from patients with previous seasonal
701 coronavirus infection collected for routine clinical testing at the Regional Hospital Feldkirch. Sera with
702 PCR-confirmed hCoV infection (hCoV 229-E, n=3; hCoV NL63, n=2 [one of which with 229E co-infection],
703 hCoV OC43, n=2; non-typed, n=2) were drawn between January 2019 and February 2020 and were kindly
704 provided by Andreas Leihner (Vorarlberg Institute for Vascular Investigation and Treatment VIVIT,
705 Dornbirn, AT). A set of 14 sera of the above (not including hCoV sera) was used for pre-validation of SARS-
706 CoV-2 antigens in an ELISA. Samples (except for those from patients after seasonal coronavirus infection)
707 were processed and stored according to standard operating procedures within the MedUni Wien Biobank
708 facility in a certified (ISO 9001:2015) environment (69)

709 **Pre-COVID Cohort, Austrian Institute of Technology**

710 Control sera from AIT covered 210 samples of blood donors were obtained in 2014 from the Austrian Red
711 Cross blood bank; collected samples have been stored at -80°C without any freeze thaw cycles.

712 **5.6 Pre-validation of antigens using seroreactivity assays**

713 **5.6.1 Luminex Assay**

714 In-house produced SARS-CoV-2 RBD, tRBD and NP as well as spike proteins of hCoV HKU-1, OC43, NL63
715 and 229E (all from Sino Biological Inc, Beijing, CN) were separately coupled to MagPlex carboxylated
716 polystyrene microspheres (Luminex Corporation, Austin, TX) according to the manufacturer's instruction,
717 with the following minor modifications: For coupling, five µg of each antigen was used per one million
718 microspheres. Coupling was performed in a total volume of 500 µL in 96-Well Protein LoBind Deepwell
719 plates (Eppendorf, Hamburg, DE) and plates were incubated at 600 rpm on a Heidolph Titramax 1000 plate
720 shaker (Heidolph, Schwabach, DE). After each incubation step plates were centrifuged at 400 g for one
721 minute. To collect the microspheres at the bottom of the plate, plates were placed on a Magnetic plate
722 separator (Luminex Corporation, Austin, TX) and the supernatant was poured off by inverting the plates.

723 Coupling was performed in 200 μ L coupling buffer (50 mM MES, pH 5.0). Microspheres with coupled
724 proteins were stored in Assay buffer (PBS supplemented with 1% (w/V) BSA, 0.05% (w/V) NaN_3 , pH 7.4) at
725 a final concentration of 10,000 microspheres per μ L at 4°C in the dark. Sera of patients and controls were
726 five-fold diluted in PBS-Triton X-100 buffer (PBS supplemented with 1% (V/V) Triton X-100, 0.05% (w/V)
727 NaN_3 , pH 7.4) and were further diluted 240-fold with Assay buffer. Coupled microspheres (800 beads per
728 sample) were first equilibrated to room temperature for 30 min. Plates were then vortexed for 30 sec and
729 sonicated for 20 sec using a Transsonic T470/H sonicator (Elma Electronics, Wetzikon, CH). The required
730 amounts (based on multiples of samples to be analyzed) of microspheres (+10% excess) were transferred
731 to 1.5 mL Protein LoBind tubes (Eppendorf, Hamburg, DE) and centrifuged for 3 min at 1,200 g. Microtubes
732 were then placed on a Magneto Dynal magnetic tube separator (Invitrogen, Carlsbad, CA), supernatants
733 were carefully removed and microspheres were resuspended in 200 μ L Assay buffer. Different
734 microspheres were then combined in a 50 mL Falcon tube to yield a total of 800 microspheres per coupled
735 antigen in 30 μ L assay buffer per single measurement. Thirty μ L of the mixed microsphere suspension was
736 then transferred to wells of a clear 96-well microplate (Corning Inc, Corning, NY). Assay plates were placed
737 on the magnetic plate separator and supernatants were poured off by inverting the plates. Fifty μ L of sera
738 (1:1,200-diluted) or assay buffer (blank samples) was applied to each well. Assays were incubated for two
739 hours at RT on the plate shaker (600 rpm). Assay plates were placed on the magnetic plate holder and the
740 supernatants were poured off by inverting the plates. Microspheres were washed by removing the
741 magnetic plate holder and the addition of 100 μ L Wash buffer (PBS; 0.05% (V/V) Tween-20; 0.05% (w/V)
742 NaN_3 ; pH 7.4) per well. After two minutes of incubation at room temperature, plates were again placed
743 on the magnetic plate holder and supernatants were poured off. After three wash steps 50 μ L of a 1:1
744 mixture of 2.5 μ g/mL goat anti-human R-Phyco AffiniPure F(ab')₂, Fc γ -specific (# 109-116-098) and F(ab')₂-
745 specific IgG (# 109-116-097, both Jackson ImmunoResearch Laboratories Inc., West Grove, PA) in Assay
746 buffer were added. Plates were incubated for 1 h at room temperature on the plate shaker (600 rpm) in

747 the dark. Microspheres were then washed again three times and microspheres were resuspended in 100
748 μ L Assay buffer and median fluorescence intensity (MFI) was immediately measured on a Flexmap 3D
749 Suspension Array System (BioRad, Hercules, CA) with a minimal Count of 100 per microsphere type, a DD
750 Gating of 7,500-25,000 and the Reporter Gain set to "Enhanced PMT (high)". MFI values were extracted
751 from FM3D result files. A minimum microsphere count of 25 counts was set as cut-off. All samples and
752 single bead types analysed fulfilled the minimum bead count criterium. FM3D results files were compiled
753 in Microsoft Excel and were log₂-transformed and blank-corrected by subtracting the mean MFI values of
754 blank samples (assay buffer only) from MFI values of the test samples.

755 **5.6.2 ELISA Assay**

756 Initially, ELISA conditions were optimized in terms of antigen coating conditions (0.5 – 8 μ g/mL) and
757 serum-dilutions (1:50 – 1:3,200) to optimize the tradeoff between background seroreactivity and
758 sensitivity in samples from individuals with weak antibody responses. The final protocol was as follows:
759 SARS CoV-2 and hCoV antigens (see above) were diluted to 6 μ g/mL in phosphate-buffered saline (PAN
760 Biotech #P-04-36500) and 50 μ L were added to each well of MaxiSorp 96-well plates (Thermo #442404).
761 After incubation at 4°C overnight, wells were washed 3x with PBS + 0.1% Tween-20 (Merck #8.22184, PBS-
762 T) and blocked for 1 hour at room temperature with PBS-T + 3% (w/V) milk powder (Fluka #70166). Serum
763 samples were diluted 1:200 in PBS-T + 1% (w/V) milk powder. 100 μ L were applied to each well and plates
764 were incubated for 2 h at RT with shaking (450 rpm). Plates were washed 4x before incubation with goat
765 anti-human IgG (Fc-specific) horseradish peroxidase (HRP) conjugated antibodies (Sigma #A0170;
766 1:50,000 in PBS-T + 1% (w/V) milk powder, 50 μ L/well) for 1 h at RT while shaking. After 4 washes, freshly
767 prepared substrate solution (substrate buffer [10 mM sodium acetate in dH₂O, pH 5, adjusted with citric
768 acid] + 1:60 TMB-stock [0.4 % Tetramethylbenzidine (Fluka #87748) in DMSO] + 1:300 H₂O₂ [0.6% in dH₂O])
769 was applied (150 μ L/well) and plates were incubated for 25 minutes at RT with shaking. Reactions were

770 stopped by the addition of 1 M sulfuric acid (25 μ L/well). Absorbance was measured at 450 nm on a Tecan
771 Sunrise Microplate reader using a reference wavelength of 620 nm and the Magellan V 7.2 SP1 Software.

772 **5.7 TECHNOZYM Anti-SARS-CoV-2 RBD and NP IgG ELISAs Assays**

773 The above-described methodology was slightly adapted for the development of the TECHNOZYM Anti
774 SARS-CoV-2 NP and RBD IgG ELISA test kits (Technoclone, Vienna, AT). The tests plates were provided with
775 the antigens coated at a concentration of 6 μ g/mL and lyophilized according to a proprietary in-house
776 protocol. The RBD test kit employs the described tRBD as coating antigen. To allow for a quantitative
777 measurement of SARS-CoV-2 antibody levels, a calibrator set consisting of five calibrators with assigned
778 values was provided for the creation of a calibration curve and was run in parallel with the patients'
779 samples. The calibrated values were established using the monoclonal antibody CR3022 as a reference
780 material, with 1 U equivalent to 100 ng/mL mAb CR3022 (#Ab01680-10.0, Absolute Antibody, Oxford, UK).
781 The calibrator set covered the concentration range 0 – 100 U/mL and concentrations of anti SARS-CoV-2
782 IgG antibodies recognizing either tRBD or NP in patient sera could be read directly from the calibration
783 curve.

784 **5.8 Technozym NP and RBD IgG ELISA Test validations**

785 The established NP and RBD IgG ELISA assays were either processed manually and analyzed on a Filtermax
786 F5 plate reader (Molecular Devices, San José, USA) or on an Immunomat instrument (Serion Diagnostics,
787 Würzburg, DE) according to the manufacturer's instructions. IgG antibody levels were reported as numeric
788 values in form of arbitrary U/mL derived from the five-point calibration curve. Cut-offs for test validations
789 were determined by ROC-analysis and the non-parametric 99th right-sided percentile method (CLSI C28-
790 A3). Sensitivities, specificities, PPV, and negative predictive values (NPV, both at 5% estimated
791 seroprevalence) were calculated. ROC-analysis data from automated tests (including Abbott ARCHITECT

792 SARS-CoV-2 IgG, DiaSorin LIAISON® Anti-SARS-CoV-2 S1/S2 IgG) were available for 64 of the positive and
793 1117 of the negative samples from a previously published study (30).

794 **5.9 SARS-CoV-2 Neutralisation Assay**

795 A tissue culture infectious dose (TCID₅₀) assay for authentic SARS-CoV-2 virus was developed for the
796 determination of neutralizing antibodies. The virus was originally isolated from a clinical specimen, a
797 nasopharyngeal swab taken in mid-March 2020 from a 25-year old male patient in Lower Austria, and was
798 further passaged twice on Vero E6 TMPRSS-2 cells in Dulbecco's modified Eagle's medium (DMEM) with
799 10% (V/V) fetal bovine serum (FBS). Vero E6 TMPRSS-2 cells, initially described in Hoffmann *et al.* (70) were
800 kindly provided by Stefan Pöhlmann; Deutsches Primatenzentrum, Göttingen, Germany.

801 Briefly, assays were performed with Vero 76 clone E6 cells (CCLV-RIE929, Friedrich-Loeffler-Institute,
802 Riems, Germany) cultured in minimum essential medium Eagle (E-MEM) with BioWhittaker Hank's
803 balanced salt solution (HBSS) (Lonza, Basel, CH) supplemented with 10% (V/V) FBS (Corning Inc, Corning,
804 NY). Neutralizing antibody titers in human serum and plasma were determined as previously described
805 (71) with the following alterations: the heat-treated sera were diluted 1:4 in triplicates in serum-free
806 HEPES-buffered DMEM medium. In the case neutralizing antibody titers were determined in human
807 lithium heparin plasma, no heat-treatment was applied and the medium was supplemented with 1x
808 Antibiotic/Antimycotic solution (Thermo Fisher Scientific, Waltham, MA). The heat treatment had no
809 effect on neutralizing titers, as verified in a pre-experiment on SARS-CoV-2 positive and negative plasma
810 samples. In addition, a toxicity control, which was processed the same way as plasma samples, was
811 included. Here, no virus was added, to prevent a false readout of the assay. Cytopathic effect (CPE) was
812 evaluated and scored for each well using an inverted optical microscope. To determine neutralization titer
813 the reciprocal of the highest serum dilution that protected more than 50% of the cells from the CPE was
814 used and was calculated according to Reed and Muench (72) .Briefly, assays were performed with Vero

815 76 clone E6 cells (CCLV-RIE929, Friedrich-Loeffler-Institute, Riems, Germany) cultured in minimum
816 essential medium Eagle (E-MEM) with Hank's balanced salt solution (HBSS) (BioWhittaker, Lonza, Szabo
817 Scandic, Austria) supplemented with 10% (v/v) fetal bovine serum (Corning, Szabo Scandic, Austria) (FBS).
818 For the assay both sera and plasma was used.

819 **5.10 Statistical analyses**

820 Raw data were assessed for normality of distribution and homogeneity of variances using the D'Agostino–
821 Pearson omnibus test before statistical procedures. Differences in median seroreactivities between pre-
822 COVID and COVID sera were compared using the Mann-Whitney U tests on blank-corrected log₂-
823 transformed median fluorescence intensities (Luminex data) or OD₄₉₀ absorbances (ELISA), respectively.
824 Correlation analyses of nonparametric data were performed by Spearman's rank-order correlation (r_s),
825 otherwise Pearson's correlation (r) was used. Relative IgG signals of outliers against SARS-CoV-2 and hCoV
826 antigens were compared by One-Way ANOVA followed by a Sidak test to correct for multiple comparisons.
827 ROC-analysis data from automated tests were compared to the established ELISA tests according to
828 DeLong. Sensitivities and specificities were compared by z-tests. Data on the diagnostic performances of
829 antigens and cross-reactivity were analyzed using Graphpad Prism Version 8.1.0 (GraphPad Software, San
830 Diego, CA, USA) Validation data were analyzed using MedCalc v19 (MedCalc Software, Ostend, Belgium)
831 and Analyse-it 5.66 (Analyse-it Software, Leeds, UK) and SPSS 23.0 (SPSS Inc.). Data from SARS-CoV-2 acute
832 sera from hospitalized individuals or outpatients obtained by the B&S Central Laboratory Linz were
833 statistically analyzed with the MedCalc 13.1.2.0.

834

835 References

- 836 1. Q.-X. Long, B.-Z. Liu, H.-J. Deng, G.-C. Wu, K. Deng, Y.-K. Chen, P. Liao, J.-F. Qiu, Y. Lin, X.-F. Cai, D.-Q.
837 Wang, Y. Hu, J.-H. Ren, N. Tang, Y.-Y. Xu, L.-H. Yu, Z. Mo, F. Gong, X.-L. Zhang, W.-G. Tian, L. Hu, X.-
838 X. Zhang, J.-L. Xiang, H.-X. Du, H.-W. Liu, C.-H. Lang, X.-H. Luo, S.-B. Wu, X.-P. Cui, Z. Zhou, M.-M. Zhu,
839 J. Wang, C.-J. Xue, X.-F. Li, L. Wang, Z.-J. Li, K. Wang, C.-C. Niu, Q.-J. Yang, X.-J. Tang, Y. Zhang, X.-M.
840 Liu, J.-J. Li, D.-C. Zhang, F. Zhang, P. Liu, J. Yuan, Q. Li, J.-L. Hu, J. Chen, A.-L. Huang, Antibody
841 responses to SARS-CoV-2 in patients with COVID-19. *Nature Medicine*. **26**, 845–848 (2020).
- 842 2. Foundation for Innovative New Diagnostics (FIND), SARS-CoV-2 diagnostic pipeline, accessed
843 January 17, 2021 (available at [https://www.finddx.org/covid-](https://www.finddx.org/covid-19/pipeline/?avance=Commercialized&type=Manual+or+automated+immunoassays&test_target=Antibody&status=all§ion=immunoassays&action=default#diag_tab)
844 [19/pipeline/?avance=Commercialized&type=Manual+or+automated+immunoassays&test_target=](https://www.finddx.org/covid-19/pipeline/?avance=Commercialized&type=Manual+or+automated+immunoassays&test_target=Antibody&status=all§ion=immunoassays&action=default#diag_tab)
845 [Antibody&status=all§ion=immunoassays&action=default#diag_tab](https://www.finddx.org/covid-19/pipeline/?avance=Commercialized&type=Manual+or+automated+immunoassays&test_target=Antibody&status=all§ion=immunoassays&action=default#diag_tab)).
- 846 3. M. Lisboa Bastos, G. Tavaziva, S. K. Abidi, J. R. Campbell, L.-P. Haraoui, J. C. Johnston, Z. Lan, S. Law,
847 E. MacLean, A. Trajman, D. Menzies, A. Benedetti, F. Ahmad Khan, Diagnostic accuracy of serological
848 tests for covid-19: systematic review and meta-analysis. *BMJ*, m2516 (2020).
- 849 4. F. Amanat, D. Stadlbauer, S. Strohmeier, T. H. O. Nguyen, V. Chromikova, M. McMahon, K. Jiang, G.
850 A. Arunkumar, D. Jurczynszak, J. Polanco, M. Bermudez-Gonzalez, G. Kleiner, T. Aydiillo, L. Miorin, D.
851 S. Fierer, L. A. Lugo, E. M. Kojic, J. Stoeber, S. T. H. Liu, C. Cunningham-Rundles, P. L. Felgner, T.
852 Moran, A. García-Sastre, D. Caplivski, A. C. Cheng, K. Kedzierska, O. Vapalahti, J. M. Hepojoki, V.
853 Simon, F. Krammer, A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nature*
854 *Medicine*. **26**, 1033–1036 (2020).
- 855 5. J. R. Beck, E. K. Shultz, The use of relative operating characteristic (ROC) curves in test performance
856 evaluation. *Arch Pathol Lab Med*. **110**, 13–20 (1986).
- 857 6. H. Pei, J. Liu, Y. Cheng, C. Sun, C. Wang, Y. Lu, J. Ding, J. Zhou, H. Xiang, Expression of SARS-
858 coronavirus nucleocapsid protein in *Escherichia coli* and *Lactococcus lactis* for serodiagnosis and
859 mucosal vaccination. *Applied Microbiology and Biotechnology*. **68**, 220–227 (2005).
- 860 7. M. Cserjan-Puschmann, N. Lingg, P. Engele, C. Kröß, J. Loibl, A. Fischer, F. Bacher, A.-C. Frank, C.
861 Öhlknecht, C. Brocard, C. Oostenbrink, M. Berkemeyer, R. Schneider, G. Striedner, A. Jungbauer,
862 Production of Circularly Permuted Caspase-2 for Affinity Fusion-Tag Removal: Cloning, Expression in
863 *Escherichia coli*, Purification, and Characterization. *Biomolecules*. **10**, 1592 (2020).
- 864 8. P. Stargardt, L. Feuchtenhofer, M. Cserjan-Puschmann, G. Striedner, J. Mairhofer, Bacteriophage
865 Inspired Growth-Decoupled Recombinant Protein Production in *Escherichia coli*. *ACS Synthetic*
866 *Biology*. **9**, 1336–1348 (2020).
- 867 9. J. De Vos, P. P. Aguilar, A. Fischer, C. Köppl, F. Strobl, F. Weiss, C. Grünwald-Gruber, M. Dürkop, M.
868 Klausberger, J. Mairhofer, G. Striedner, A. Jungbauer, M. Cserjan-Puschmann, N. Lingg,
869 Comprehensive characterization of highly pure SARS-CoV-2 nucleocapsid protein produced in
870 *Escherichia coli* by native chromatography. *submitted to: J Analyt Chem*.
- 871 10. T. Perkmann, N. Perkmann-Nagele, M. Oszvar-Kozma, T. Koller, M.-K. Breyer, R. Breyer-Kohansal, O.
872 C. Burghuber, S. Hartl, D. Aletaha, D. Sieghart, P. Quehenberger, R. Marculescu, P. Mucher, A.
873 Radakovics, R. Strassl, G. Leitner, O. F. Wagner, C. J. Binder, H. Haslacher, “Increasing both specificity

- 874 and sensitivity of SARS-CoV-2 antibody tests by using an adaptive orthogonal testing approach”
875 (preprint, *Infectious Diseases (except HIV/AIDS)*, 2020), , doi:10.1101/2020.11.05.20226449.
- 876 11. S. E. F. Yong, D. E. Anderson, W. E. Wei, J. Pang, W. N. Chia, C. W. Tan, Y. L. Teoh, P. Rajendram, M.
877 P. H. S. Toh, C. Poh, V. T. J. Koh, J. Lum, N.-A. M. Suhaimi, P. Y. Chia, M. I.-C. Chen, S. Vasoo, B. Ong,
878 Y. S. Leo, L. Wang, V. J. M. Lee, Connecting clusters of COVID-19: an epidemiological and serological
879 investigation. *The Lancet Infectious Diseases*. **20**, 809–815 (2020).
- 880 12. L. Yue, H. Cao, T. Xie, R. Long, H. Li, T. Yang, M. Yan, Z. Xie, N-terminally truncated nucleocapsid
881 protein of SARS-CoV-2 as a better serological marker than whole nucleocapsid protein in evaluating
882 the immunogenicity of inactivated SARS-CoV-2. *Journal of Medical Virology* (2020),
883 doi:10.1002/jmv.26541.
- 884 13. A. Rump, R. Risti, M.-L. Kristal, J. Reut, V. Syritski, A. Lookene, S. Ruutel Boudinot, Dual ELISA using
885 SARS-CoV-2 nucleocapsid protein produced in *E. coli* and CHO cells reveals epitope masking by N-
886 glycosylation. *Biochemical and Biophysical Research Communications* (2020),
887 doi:10.1016/j.bbrc.2020.11.060.
- 888 14. K. Rattanapisit, B. Shanmugaraj, S. Manopwisedjaroen, P. B. Purwono, K. Siri wattananon, N.
889 Khorattanakulchai, O. Hanittinan, W. Boonyayothin, A. Thitithanyanont, D. R. Smith, W.
890 Phoolcharoen, Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific
891 monoclonal antibody CR3022 in *Nicotiana benthamiana*. *Scientific Reports*. **10** (2020),
892 doi:10.1038/s41598-020-74904-1.
- 893 15. D. Das, M. R. Suresh, Copious production of SARS-CoV nucleocapsid protein employing codon
894 optimized synthetic gene. *J Virol Methods*. **137**, 343–346 (2006).
- 895 16. P. Pino, J. Kint, D. Kiseljak, V. Agnolon, G. Corradin, A. V. Kajava, P. Rovero, R. Dijkman, G. den Hartog,
896 J. S. McLellan, P. O. Byrne, M. J. Wurm, F. M. Wurm, Trimeric SARS-CoV-2 Spike Proteins Produced
897 from CHO Cells in Bioreactors Are High-Quality Antigens. *Processes*. **8**, 1539 (2020).
- 898 17. M. V. Sinegubova, N. A. Orlova, S. V. Kovnir, L. K. Dayanova, I. I. Vorobiev, “High-level expression of
899 the monomeric SARS-CoV-2 S protein RBD 320-537 in stably transfected CHO cells by the *EEF1A1* -
900 based plasmid vector” (preprint, *Biochemistry*, 2020), , doi:10.1101/2020.11.04.368092.
- 901 18. D. Palmberger, K. Ashjaei, S. Strell, K. Hoffmann-Sommergruber, R. Grabherr, Minimizing
902 fucosylation in insect cell-derived glycoproteins reduces binding to IgE antibodies from the sera of
903 patients with allergy. *Biotechnology Journal*. **9**, 1206–1214 (2014).
- 904 19. V. Roy, S. Fischinger, C. Atyeo, M. Slein, C. Loos, A. Balazs, C. Luedemann, M. G. Astudillo, D. Yang,
905 D. R. Wesemann, R. Charles, A. J. Lafrate, J. Feldman, B. Hauser, T. Caradonna, T. E. Miller, M. R.
906 Murali, L. Baden, E. Nilles, E. Ryan, D. Lauffenburger, W. G. Beltran, G. Alter, SARS-CoV-2-specific
907 ELISA development. *Journal of Immunological Methods*. **484–485**, 112832 (2020).
- 908 20. T. A. Alandijany, S. A. El-Kafrawy, A. M. Tolah, S. S. Sohrab, A. A. Faizo, A. M. Hassan, T. L. Alsubhi, N.
909 A. Othman, E. I. Azhar, Development and Optimization of In-house ELISA for Detection of Human
910 IgG Antibody to SARS-CoV-2 Full Length Spike Protein. *Pathogens*. **9**, 803 (2020).

- 911 21. E. Marklund, S. Leach, H. Axelsson, K. Nyström, H. Norder, M. Bemark, D. Angeletti, A. Lundgren, S.
912 Nilsson, L.-M. Andersson, A. Yilmaz, M. Lindh, J.-Å. Liljeqvist, M. Gisslén, Serum-IgG responses to
913 SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders. *PLOS ONE*.
914 **15**, e0241104 (2020).
- 915 22. E. H. Kang, Y.-J. Ha, Y. J. Lee, Autoantibody Biomarkers in Rheumatic Diseases. *International Journal*
916 *of Molecular Sciences*. **21**, 1382 (2020).
- 917 23. Y. Wang, S. Sun, H. Shen, L. Jiang, M. Zhang, D. Xiao, Y. Liu, X. Ma, Y. Zhang, N. Guo, T. Jia, Cross-
918 reaction of SARS-CoV antigen with autoantibodies in autoimmune diseases. *Cell Mol Immunol*. **1**,
919 304–307 (2004).
- 920 24. Q.-X. Long, X.-J. Tang, Q.-L. Shi, Q. Li, H.-J. Deng, J. Yuan, J.-L. Hu, W. Xu, Y. Zhang, F.-J. Lv, K. Su, F.
921 Zhang, J. Gong, B. Wu, X.-M. Liu, J.-J. Li, J.-F. Qiu, J. Chen, A.-L. Huang, Clinical and immunological
922 assessment of asymptomatic SARS-CoV-2 infections. *Nature Medicine*. **26**, 1200–1204 (2020).
- 923 25. A. Bryan, G. Pepper, M. H. Wener, S. L. Fink, C. Morishima, A. Chaudhary, K. R. Jerome, P. C. Mathias,
924 A. L. Greninger, Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and
925 Seroprevalence in Boise, Idaho. *Journal of Clinical Microbiology*. **58** (2020), doi:10.1128/JCM.00941-
926 20.
- 927 26. K. Harley, I. L. Gunsolus, Comparison of the Clinical Performances of the Abbott Alinity IgG, Abbott
928 Architect IgM, and Roche Elecsys Total SARS-CoV-2 Antibody Assays. *Journal of Clinical Microbiology*.
929 **59**, e02104-20 (2020).
- 930 27. A. J. Jääskeläinen, S. Kuivanen, E. Kekäläinen, M. J. Ahava, R. Loginov, H. Kallio-Kokko, O. Vapalahti,
931 H. Jarva, S. Kurkela, M. Lappalainen, “Performance of six SARS-CoV-2 immunoassays in comparison
932 with microneutralisation” (preprint, Infectious Diseases (except HIV/AIDS), 2020), ,
933 doi:10.1101/2020.05.18.20101618.
- 934 28. Statistik Austria, Medical University of Vienna, “In the middle/end of October 2020, 4.7% of the
935 Austrian population had antibodies to SARS-CoV-2. Extrapolation of Austria-wide COVID 19
936 prevalence study,” accessed January 17, 2021 (available at
937 [https://www.meduniwien.ac.at/web/en/ueber-uns/news/detailseite/2020/news-im-dezember-](https://www.meduniwien.ac.at/web/en/ueber-uns/news/detailseite/2020/news-im-dezember-2020/47-der-oesterreichischen-bevoelkerung-hatten-mitte/ende-oktober-2020-antikoerper-gegen-sars-cov-2/)
938 [2020/47-der-oesterreichischen-bevoelkerung-hatten-mitte/ende-oktober-2020-antikoerper-](https://www.meduniwien.ac.at/web/en/ueber-uns/news/detailseite/2020/news-im-dezember-2020/47-der-oesterreichischen-bevoelkerung-hatten-mitte/ende-oktober-2020-antikoerper-gegen-sars-cov-2/)
939 [gegen-sars-cov-2/](https://www.meduniwien.ac.at/web/en/ueber-uns/news/detailseite/2020/news-im-dezember-2020/47-der-oesterreichischen-bevoelkerung-hatten-mitte/ende-oktober-2020-antikoerper-gegen-sars-cov-2/)).
- 940 29. A. Rostami, M. Sepidarkish, M. M. G. Leeflang, S. M. Riahi, M. Nourollahpour Shiadeh, S. Esfandyari,
941 A. H. Mokdad, P. J. Hotez, R. B. Gasser, SARS-CoV-2 seroprevalence worldwide: a systematic review
942 and meta-analysis. *Clinical Microbiology and Infection* (2020), doi:10.1016/j.cmi.2020.10.020.
- 943 30. T. Perkmann, N. Perkmann-Nagele, M.-K. Breyer, R. Breyer-Kohansal, O. C. Burghuber, S. Hartl, D.
944 Aletaha, D. Sieghart, P. Quehenberger, R. Marculescu, P. Mucher, R. Strassl, O. F. Wagner, C. J.
945 Binder, H. Haslacher, Side-by-Side Comparison of Three Fully Automated SARS-CoV-2 Antibody
946 Assays with a Focus on Specificity. *Clinical Chemistry*. **66**, 1405–1413 (2020).
- 947 31. L. S. Pflüger, J. H. Bannasch, T. T. Brehm, S. Pfefferle, A. Hoffmann, D. Nörz, M. van der Meirschen,
948 S. Kluge, M. Haddad, S. Pischke, J. Hiller, M. M. Addo, A. W. Lohse, J. Schulze zur Wiesch, S. Peine,
949 M. Aepfelbacher, M. Lütgehetmann, Clinical evaluation of five different automated SARS-CoV-2

- 950 serology assays in a cohort of hospitalized COVID-19 patients. *Journal of Clinical Virology*. **130**,
951 104549 (2020).
- 952 32. T. J. Ripperger, J. L. Uhrlaub, M. Watanabe, R. Wong, Y. Castaneda, H. A. Pizzato, M. R. Thompson,
953 C. Bradshaw, C. C. Weinkauff, C. Bime, H. L. Erickson, K. Knox, B. Bixby, S. Parthasarathy, S. Chaudhary,
954 B. Natt, E. Cristan, T. El Aini, F. Rischard, J. Champion, M. Chopra, M. Insel, A. Sam, J. L. Knepler, A. P.
955 Capaldi, C. M. Spier, M. D. Dake, T. Edwards, M. E. Kaplan, S. J. Scott, C. Hypes, J. Mosier, D. T. Harris,
956 B. J. LaFleur, R. Sprissler, J. Nikolich-Žugich, D. Bhattacharya, Orthogonal SARS-CoV-2 Serological
957 Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity.
958 *Immunity*. **53**, 925-933.e4 (2020).
- 959 33. CDC Centers for Disease Control and Prevention, “Interim Guidelines for COVID-19 Antibody Testing
960 in Clinical and Public Health Settings” (2020), accessed January 17, 2021 (available at
961 <https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html>).
- 962 34. P. C. Y. Woo, S. K. P. Lau, B. H. L. Wong, H. -w. Tsoi, A. M. Y. Fung, R. Y. T. Kao, K. -h. Chan, J. S. M.
963 Peiris, K. -y. Yuen, Differential Sensitivities of Severe Acute Respiratory Syndrome (SARS)
964 Coronavirus Spike Polypeptide Enzyme-Linked Immunosorbent Assay (ELISA) and SARS Coronavirus
965 Nucleocapsid Protein ELISA for Serodiagnosis of SARS Coronavirus Pneumonia. *Journal of Clinical
966 Microbiology*. **43**, 3054–3058 (2005).
- 967 35. Y.-J. Tan, P.-Y. Goh, B. C. Fielding, S. Shen, C.-F. Chou, J.-L. Fu, H. N. Leong, Y. S. Leo, E. E. Ooi, A. E.
968 Ling, S. G. Lim, W. Hong, Profiles of Antibody Responses against Severe Acute Respiratory Syndrome
969 Coronavirus Recombinant Proteins and Their Potential Use as Diagnostic Markers. *Clinical Diagnostic
970 Laboratory Immunology*. **11**, 362–371 (2004).
- 971 36. S. E. Turbett, M. Anahtar, A. S. Dighe, W. Garcia Beltran, T. Miller, H. Scott, S. M. Durbin, M.
972 Bharadwaj, J. Thomas, T. S. Gogakos, M. Astudillo, J. Lennerz, E. S. Rosenberg, J. A. Branda,
973 Evaluation of Three Commercial SARS-CoV-2 Serologic Assays and Their Performance in Two-Test
974 Algorithms. *Journal of Clinical Microbiology*. **59** (2020), doi:10.1128/JCM.01892-20.
- 975 37. M. S. Suthar, M. G. Zimmerman, R. C. Kauffman, G. Mantus, S. L. Linderman, W. H. Hudson, A.
976 Vanderheiden, L. Nyhoff, C. W. Davis, O. Adekunle, M. Affer, M. Sherman, S. Reynolds, H. P.
977 Verkerke, D. N. Alter, J. Guarner, J. Bryksin, M. C. Horwath, C. M. Arthur, N. Saakadze, G. H. Smith,
978 S. Edupuganti, E. M. Scherer, K. Hellmeister, A. Cheng, J. A. Morales, A. S. Neish, S. R. Stowell, F.
979 Frank, E. Ortlund, E. J. Anderson, V. D. Menachery, N. Rouphael, A. K. Mehta, D. S. Stephens, R.
980 Ahmed, J. D. Roback, J. Wrammert, Rapid Generation of Neutralizing Antibody Responses in COVID-
981 19 Patients. *Cell Reports Medicine*. **1**, 100040 (2020).
- 982 38. F. Wu, M. Liu, A. Wang, L. Lu, Q. Wang, C. Gu, J. Chen, Y. Wu, S. Xia, Y. Ling, Y. Zhang, J. Xun, R. Zhang,
983 Y. Xie, S. Jiang, T. Zhu, H. Lu, Y. Wen, J. Huang, Evaluating the Association of Clinical Characteristics
984 With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in
985 Shanghai, China. *JAMA Internal Medicine*. **180**, 1356 (2020).
- 986 39. D. Sterlin, A. Mathian, M. Miyara, A. Mohr, F. Anna, L. Claër, P. Quentric, J. Fadlallah, H. Devilliers, P.
987 Ghillani, C. Gunn, R. Hockett, S. Mudumba, A. Guihot, C.-E. Luyt, J. Mayaux, A. Beurton, S. Fourati, T.
988 Bruel, O. Schwartz, J.-M. Lacorte, H. Yssel, C. Parizot, K. Dorgham, P. Charneau, Z. Amoura, G.
989 Gorochov, IgA dominates the early neutralizing antibody response to SARS-CoV-2. *Science
990 Translational Medicine*, eabd2223 (2020).

- 991 40. S. T. H. Liu, H.-M. Lin, I. Baine, A. Wajnberg, J. P. Gumprecht, F. Rahman, D. Rodriguez, P. Tandon, A.
992 Bassily-Marcus, J. Bander, C. Sanky, A. Dupper, A. Zheng, F. T. Nguyen, F. Amanat, D. Stadlbauer, D.
993 R. Altman, B. K. Chen, F. Krammer, D. R. Mendu, A. Firpo-Betancourt, M. A. Levin, E. Bagiella, A.
994 Casadevall, C. Cordon-Cardo, J. S. Jhang, S. A. Arinsburg, D. L. Reich, J. A. Aberg, N. M. Bouvier,
995 Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study.
996 *Nature Medicine*. **26**, 1708–1713 (2020).
- 997 41. Food and Drug Administration (FDA), Recommendations for Investigational COVID-19 Convalescent
998 Plasma (2020), accessed January 17, 2021 (available at <https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma#compliance>).
- 1001 42. W. T. Lee, R. C. Girardin, A. P. Dupuis, K. E. Kulas, A. F. Payne, S. J. Wong, S. Arinsburg, F. T. Nguyen,
1002 D. R. Mendu, A. Firpo-Betancourt, J. Jhang, A. Wajnberg, F. Krammer, C. Cordon-Cardo, S. Amler, M.
1003 Montecalvo, B. Hutton, J. Taylor, K. A. McDonough, Neutralizing Antibody Responses in COVID-19
1004 Convalescent Sera. *The Journal of Infectious Diseases*. **223**, 47–55 (2021).
- 1005 43. F. Wu, S. Zhao, B. Yu, Y.-M. Chen, W. Wang, Z.-G. Song, Y. Hu, Z.-W. Tao, J.-H. Tian, Y.-Y. Pei, M.-L.
1006 Yuan, Y.-L. Zhang, F.-H. Dai, Y. Liu, Q.-M. Wang, J.-J. Zheng, L. Xu, E. C. Holmes, Y.-Z. Zhang, A new
1007 coronavirus associated with human respiratory disease in China. *Nature*. **579**, 265–269 (2020).
- 1008 44. F. Sainsbury, E. C. Thuenemann, G. P. Lomonosoff, pEAQ: versatile expression vectors for easy and
1009 quick transient expression of heterologous proteins in plants. *Plant Biotechnology Journal*. **7**, 682–
1010 693 (2009).
- 1011 45. N. Lingg, M. Cserjan-Puschmann, A. Fischer, P. Engele, R. Schneider, C. Brocard, M. Berkemeyer, G.
1012 Striedner, A. Jungbauer, Advanced purification platform using circularly permuted caspase-2 for
1013 affinity fusion-tag removal to produce native fibroblast growth factor 2. *submitted to: J. Chem.*
1014 *Technol. Biotechnol.*
- 1015 46. X. Tian, C. Li, A. Huang, S. Xia, S. Lu, Z. Shi, L. Lu, S. Jiang, Z. Yang, Y. Wu, T. Ying, Potent binding of
1016 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody.
1017 *Emerging Microbes & Infections*. **9**, 382–385 (2020).
- 1018 47. J. Mairhofer, M. Cserjan-Puschmann, G. Striedner, K. Nöbauer, E. Razzazi-Fazeli, R. Grabherr,
1019 Marker-free plasmids for gene therapeutic applications—Lack of antibiotic resistance gene
1020 substantially improves the manufacturing process. *Journal of Biotechnology*. **146**, 130–137 (2010).
- 1021 48. J. Urthaler, C. Ascher, H. Wöhrer, R. Necina, Automated alkaline lysis for industrial scale cGMP
1022 production of pharmaceutical grade plasmid-DNA. *Journal of Biotechnology*. **128**, 132–149 (2007).
- 1023 49. Cytiva, “Application Note 28-4094-85 AA: PlasmidSelect Xtra for downstream processing of
1024 supercoiled plasmid DNA” (2020).
- 1025 50. Y. Durocher, High-level and high-throughput recombinant protein production by transient
1026 transfection of suspension-growing human 293-EBNA1 cells. *Nucleic Acids Research*. **30**, 9e–99
1027 (2002).

- 1028 51. E. Lobner, A.-S. Humm, K. Göritzer, G. Mlynek, M. G. Puchinger, C. Hasenhindl, F. Rüker, M. W.
1029 Traxlmayr, K. Djinović-Carugo, C. Obinger, Fcαb-HER2 Interaction: a Ménage à Trois. Lessons from X-
1030 Ray and Solution Studies. *Structure*. **25**, 878-889.e5 (2017).
- 1031 52. Y.-R. Chen, S. Zhong, Z. Fei, Y. Hashimoto, J. Z. Xiang, S. Zhang, G. W. Blissard, The Transcriptome of
1032 the Baculovirus *Autographa californica* Multiple Nucleopolyhedrovirus in *Trichoplusia ni* Cells.
1033 *Journal of Virology*. **87**, 6391–6405 (2013).
- 1034 53. K. Koczka, P. Peters, W. Ernst, H. Himmelbauer, L. Nika, R. Grabherr, Comparative transcriptome
1035 analysis of a *Trichoplusia ni* cell line reveals distinct host responses to intracellular and secreted
1036 protein products expressed by recombinant baculoviruses. *Journal of Biotechnology*. **270**, 61–69
1037 (2018).
- 1038 54. M. Klausberger, M. Wilde, D. Palmberger, R. Hai, R. A. Albrecht, I. Margine, A. Hirsh, A. García-Sastre,
1039 R. Grabherr, F. Krammer, One-shot vaccination with an insect cell-derived low-dose influenza A H7
1040 virus-like particle preparation protects mice against H7N9 challenge. *Vaccine*. **32**, 355–362 (2014).
- 1041 55. R. Strasser, J. Stadlmann, M. Schähs, G. Stiegler, H. Quendler, L. Mach, J. Glössl, K. Weterings, M.
1042 Pabst, H. Steinkellner, Generation of glyco-engineered *Nicotiana benthamiana* for the production of
1043 monoclonal antibodies with a homogeneous human-like N-glycan structure: XylT and FucT down-
1044 regulation in *N. benthamiana*. *Plant Biotechnology Journal*. **6**, 392–402 (2008).
- 1045 56. A. Castilho, P. Gattinger, J. Grass, J. Jez, M. Pabst, F. Altmann, M. Gorfer, R. Strasser, H. Steinkellner,
1046 N-Glycosylation engineering of plants for the biosynthesis of glycoproteins with bisected and
1047 branched complex N-glycans. *Glycobiology*. **21**, 813–823 (2011).
- 1048 57. K. Göritzer, A. Turupcu, D. Maresch, J. Novak, F. Altmann, C. Oostenbrink, C. Obinger, R. Strasser,
1049 Distinct Fcα receptor N-glycans modulate the binding affinity to immunoglobulin A (IgA) antibodies.
1050 *Journal of Biological Chemistry*. **294**, 13995–14008 (2019).
- 1051 58. E. C. Hulme, M. A. Trevethick, Ligand binding assays at equilibrium: validation and interpretation:
1052 Equilibrium binding assays. *British Journal of Pharmacology*. **161**, 1219–1237 (2010).
- 1053 59. D. A. Armbruster, T. Pry, Limit of blank, limit of detection and limit of quantitation. *Clin Biochem Rev*.
1054 **29 Suppl 1**, S49-52 (2008).
- 1055 60. S. B. Carvalho, A. S. Moreira, J. Gomes, M. J. T. Carrondo, D. J. Thornton, P. M. Alves, J. Costa, C.
1056 Peixoto, A detection and quantification label-free tool to speed up downstream processing of model
1057 mucins. *PLOS ONE*. **13**, e0190974 (2018).
- 1058 61. J. S. Klein, P. J. Bjorkman, Few and Far Between: How HIV May Be Evading Antibody Avidity. *PLoS*
1059 *Pathogens*. **6**, e1000908 (2010).
- 1060 62. T. Hattori, D. Lai, I. S. Dementieva, S. P. Montañó, K. Kurosawa, Y. Zheng, L. R. Akin, K. M. Świst-
1061 Rosowska, A. T. Grzybowski, A. Koide, K. Krajewski, B. D. Strahl, N. L. Kelleher, A. J. Ruthenburg, S.
1062 Koide, Antigen clasping by two antigen-binding sites of an exceptionally specific antibody for histone
1063 methylation. *Proceedings of the National Academy of Sciences*. **113**, 2092–2097 (2016).

- 1064 63. J. Wallner, G. Lhota, M. Schosserer, K. Vorauer-Uhl, An approach for liposome immobilization using
1065 sterically stabilized micelles (SSMs) as a precursor for bio-layer interferometry-based interaction
1066 studies. *Colloids and Surfaces B: Biointerfaces*. **154**, 186–194 (2017).
- 1067 64. P. S. Katsamba, I. Navratilova, M. Calderon-Cacia, L. Fan, K. Thornton, M. Zhu, T. V. Bos, C. Forte, D.
1068 Friend, I. Laird-Offringa, G. Tavares, J. Whatley, E. Shi, A. Widom, K. C. Lindquist, S. Klakamp, A.
1069 Drake, D. Bohmann, M. Roell, L. Rose, J. Dorocke, B. Roth, B. Luginbühl, D. G. Myszka, Kinetic analysis
1070 of a high-affinity antibody/antigen interaction performed by multiple Biacore users. *Analytical*
1071 *Biochemistry*. **352**, 208–221 (2006).
- 1072 65. Y. N. Abdiche, D. S. Malashock, J. Pons, Probing the binding mechanism and affinity of tanezumab, a
1073 recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors. *Protein*
1074 *Science*. **17**, 1326–1335 (2008).
- 1075 66. C. Irsara, A. E. Egger, W. Prokop, M. Nairz, L. Loacker, S. Sahanic, T. Sonnweber, W. Mayer, H.
1076 Schennach, J. Loeffler-Ragg, R. Bellmann-Weiler, I. Tancevski, G. Weiss, M. Anliker, A. Griesmacher,
1077 G. Hoermann, “Evaluation of four commercial, fully automated SARS-CoV-2 antibody tests suggests
1078 a revision of the Siemens SARS-CoV-2 IgG assay” (preprint, Infectious Diseases (except HIV/AIDS),
1079 2020), , doi:10.1101/2020.11.27.20239590.
- 1080 67. A. Frey, J. Di Canzio, D. Zurakowski, A statistically defined endpoint titer determination method for
1081 immunoassays. *Journal of Immunological Methods*. **221**, 35–41 (1998).
- 1082 68. R. Breyer-Kohansal, S. Hartl, O. C. Burghuber, M. Urban, A. Schrott, A. Agusti, T. Sigsgaard, C.
1083 Vogelmeier, E. Wouters, M. Studnicka, M.-K. Breyer, The LEAD (Lung, Heart, Social, Body) Study:
1084 Objectives, Methodology, and External Validity of the Population-Based Cohort Study. *Journal of*
1085 *Epidemiology*. **29**, 315–324 (2019).
- 1086 69. H. Haslacher, M. Gerner, P. Hofer, A. Jurkowitsch, J. Hainfellner, R. Kain, O. F. Wagner, T. Perkmann,
1087 Usage Data and Scientific Impact of the Prospectively Established Fluid Bioresources at the Hospital-
1088 Based MedUni Wien Biobank. *Biopreservation and Biobanking*. **16**, 477–482 (2018).
- 1089 70. M. Hoffmann, H. Kleine-Weber, S. Schroeder, N. Krüger, T. Herrler, S. Erichsen, T. S. Schiergens, G.
1090 Herrler, N.-H. Wu, A. Nitsche, M. A. Müller, C. Drosten, S. Pöhlmann, SARS-CoV-2 Cell Entry Depends
1091 on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*. **181**, 271-280.e8
1092 (2020).
- 1093 71. H. Laferl, H. Kelani, T. Seitz, B. Holzer, I. Zimpernik, A. Steinrigl, F. Schmoll, C. Wenisch, F. Allerberger,
1094 An approach to lifting self-isolation for health care workers with prolonged shedding of SARS-CoV-2
1095 RNA. *Infection* (2020), doi:10.1007/s15010-020-01530-4.
- 1096 72. L. J. Reed, H. Muench, A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS¹². *American*
1097 *Journal of Epidemiology*. **27**, 493–497 (1938).
- 1098
- 1099

1100 **Acknowledgements:**

1101 We thank Florian Krammer (Icahn School of Medicine at Mount Sinai, NY, United States) for providing the
1102 constructs used for the production of RBD and CR3022. We thank George Lomonossoff (John Innes Centre,
1103 Norwich, UK) and Plant Bioscience Limited (PBL) (Norwich, UK) for supplying the pEAQ-HT expression
1104 vector. The authors thank Naila Avdic, Kristina Jagersberger, Christina Hausjell, Viktoria Mayer, Anna-
1105 Carina Frank, Sophie Vazulka, Florian Mayer, Matthias Müller, Andreas Dietrich, Mathias Fink, Florian
1106 Weiss, Giulia Borsi, Mohammed Hussein, Patrick Mairhofer, Andreas Fischer, Alexander Doleschal (all
1107 Department of Biotechnology, University of Natural Resources and Life Sciences (BOKU) Vienna or and/or
1108 ACIB GmbH affiliated) for their support in the cloning, production and analysis of SARS-CoV-2 antigens
1109 described in this work. The BLI and mass spectrometry equipment was kindly provided by the EQ-BOKU
1110 VIBT GmbH and the BOKU Core Facilities *Biomolecular & Cellular Analysis* (BmCA) and *Mass Spectrometry*.
1111 Boehringer Ingelheim RCV GmbH & Co KG fully supported the endeavor and granted access to
1112 manufacturing technologies for process development and manufacturing.

1113 The authors thank Irene Schaffner and Jakob Wallner (BOKU BmCA) for assisting in BLI measurements and
1114 ForteBio for providing SAX biosensors. The authors want to thank Maria Ozsvar-Kozma, Patrick Mucher,
1115 Manuela Repl and Astrid Radakovics (Department of Laboratory Medicine, Medical University Vienna) for
1116 outstanding technical assistance. The authors thank the following collaborators for providing biomaterial
1117 and data for ELISA evaluation: Manfred Nairz, Sabina Sahanic, Thomas Sonnweber, Alex Pizzini, Ivan
1118 Tancevski (Department of Internal Medicine II, Medical University of Innsbruck), Markus Anliker, Lorin
1119 Loacker, Wolfgang Prokop (Central Institute for Medical and Chemical Laboratory Diagnosis, Innsbruck
1120 University Hospital), Wolfgang Mayer, Harald Schennach (Central Institute for Blood Transfusion &
1121 Immunological Department, University Hospital of Innsbruck), Daniel Aletaha (Department of Internal
1122 Medicine III, Medical University of Vienna), Robab Breyer-Kohansal, Otto C Burghuber, and Sylvia Hartl

1123 (LEAD-Study - Ludwig Boltzmann Institute for Lung Health, Vienna, Austria), Andreas Leiberer (Vorarlberg
1124 Institute for Vascular Investigation and Treatment [VIVIT], Dornbirn, Austria).

1125 Finally, the BOKU Spin-off Novasign GmbH supported the sustainability concept of BOKU by creating and
1126 hosting the BOKU-COVID19 Portal (portal.boku-covid19.at) that enables researchers worldwide to obtain
1127 trial samples of the within this work described SARS-CoV-2 antigens free of charge. Armin Khodaei and
1128 Roger-Dalmau-Diaz implemented the database and interface of the portal.

1129

1130 **Funding:**

1131 We thank the Vienna Science and Technology Fund (WWTF) for partial funding of this project (Project No.
1132 COV20-016). We thank the University of Natural Resources and Life Sciences (BOKU) Vienna, the Ludwig
1133 Boltzmann Institute for Experimental and Clinical Traumatology and the Ludwig Boltzmann Gesellschaft
1134 for financial support of the project. Jelle De Vos acknowledges the Research Foundation Flanders (FWO)
1135 for support by grants 12J6520N and V443719N, and the OEAD (Austria) for scholarship ICM-2019-14929.
1136 FFG.

1137 **Author Contributions:**

1138 A.J.,A.W.,C.J.B.,E.L.,F.E.,F.G.,G.S.,G.W.K.,H.H.,J.M.,M.S.,M.D.,M.W.,M.K.,M.C.P.,N.L.,N.Bo.,N.Bi.,P.P.A.,
1139 R.G.,T.P.,W.G. designed study concepts.

1140 A.J.,A.W.,C.J.B.,F.E.,F.G.,G.S.,J.M.,M.W.,M.K.,M.C.P.,N.Bi.,R.G.,W.G. acquired financial support for this
1141 project.

1142 A.W.,B.H.,B.D.,C.J.B.,E.G.,E.L.,F.G.,G.M.,G.S.,G.SM.,G.W.K.,H.H.,J.H.,J.B.,J.M.,Li.M.,M.H.,M.E.,M.S.,M.D.,
1143 M.W.,M.K.,M.C.P.,N.L.,N.M.,N.Bi.,P.P.A.,P.S.,R.H.,R.G.,Ri.S.,T.P.,W.G. developed methodology.

1144 A.E.E.,A.G.,A.W.,B.H.,B.D.,C.I.,C.J.B.,C.K.,C.T.,C.G.G.,D.M.,D.S.,E.G.,E.L.,F.S.,G.M.,G.L.,G.SM.,G.W.K.,G.H.,
1145 J.H.,J.D.V.,J.L.R.,J.B.,Lu.M.,M.H.,M.S.,M.K.B.,M.D.,M.W.,M.K.,N.L.,N.M.,N.Bi.,P.P.A.,P.Q.,P.S.,R.H.,R.G.,Ri.
1146 S.,Ro.S.,R.B.W.,T.P.,U.V. conducting a research and investigation process, specifically performing the
1147 experiments, or data/evidence collection.

1148 K.V. developed evaluation software code.

1149 A.E.E.,A.G.,B.D.,C.I.,F.G.,G.H.,H.H.,M.D.,M.K.,R.B.W.,T.P. performed data curation.

1150 A.W.,F.G.,H.H.,J.H.,M.H.,M.S.,M.K.,W.G. performed data validation and evaluated data reproducibility.

1151 A.E.E.,A.G.,A.W.,B.H.,B.D.,C.I.,C.G.G,D.M,E.L.,F.G.,G.M.,G.SM.,G.W.K.,G.H.,H.H.,J.D.V.,K.V.,Lu.M.,M.E.,
1152 M.D.,M.K.,M.C.P.,N.L.,P.P.A.,Ri.S. performed formal analysis to analyze and synthesize data.

1153 H.H.,M.D.,M.K.,R.B.W. performed data visualization.

1154 A.E.E.,A.J.,A.G.,C.I.,C.J.B,D.S.,E.L.,F.E.,F.G.,G.S.,G.L.,G.H.,G.W.,J.D.V.,J.L.R.,J.M.,Lu.M.,M.K.B.,M.W.,M.C.P.,
1155 N.Bo.,N.Bi.,P.Q.,R.H.,R.G.,Ro.S.,R.B.W.,W.G., provided study materials, reagents, laboratory samples,
1156 animals, instrumentation, computing resources, or other analysis tools.

1157 A.W.,C.J.B,F.G.,G.S.,G.W.,Lu.M.,M.C.P,M.D.,M.K.,N.Bo.,N.Bi.,R.G.,R.B.W.,W.G. were responsible for
1158 supervising research activities and for project administration.

1159 H.H.,M.D.,M.K.,M.C.P.,R.G.,T.P. wrote the original draft.

1160 B.D.,C.J.B,E.L.,F.G.,G.W.K.,J.D.V.,J.M.,Lu.M.,M.E.,M.C.P.,N.L.,P.P.A.,P.S.,R.G.,W.G. reviewed and edited
1161 the manuscript.

1162


1163 **Competing interests:**

1164 The authors declare that they have no competing interest, but J.M. and G.S. owns an interest in enGenes
1165 Biotech GmbH, the legal entity commercializing the enGenes-X-press technology and the antigens
1166 developed within this work. C.J.B. is a board member of Technoclone. N.B. is employee of Technoclone.
1167 P.Q. is Advisory Board Member for Roche Austria, and reports personal fees from Takeda.

1168 **Data and materials availability:**

1169 All data needed to evaluate the conclusions in the paper are present in the manuscript and/or the
1170 Supplementary Materials. Recombinant SARS-CoV-2 antigens can be requested from interested
1171 researchers for research purposes under www.boku-covid19.at (after registration). For commercial
1172 purposes antigens can be requested from enGenes Biotech GmbH. Technozym NP and RBD IgG serotests
1173 are available from Technoclone (Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH,
1174 Vienna, Austria)

1175 .



1176

1177 **Fig. 1. Comparative profiling of SARS CoV-2 antigens from different expression hosts for serodiagnosis.**

1178 **A-C**, the canonical SARS-CoV-2 RBD expressed in five biotechnological platforms (HEK, CHO-K1, CHO-S,

1179 *Tnms42*, *N. benthamiana*, **left panel**), an optimized RBD construct expressed in HEK cells (tRBD) as well as

1180 the NP produced in *E. coli* (**right panel**) were compared in terms of biotechnological parameters as well

1181 as seroreactivity to identify ideal candidates that may be sustainably produced for specific and sensitive

1182 SARS-CoV-2 serodiagnosis. **A**) Pre-defined process and protein quality parameters include overall yield


1183 after purification, functional binding to the conformation-dependent mAb CR3022 (RBD) or a

1184 commercially available anti-NP antibody as verified by biolayer interferometry, as well as glycosylation

1185 analysis. Purified monomer (M), dimer (D), and NP full-length protein (FL)-content was determined by HP-

1186 SEC **B-C**, Pre-validation of antigens for serodiagnosis with sera of healthy blood donors collected prior to
1187 2018 (n=210) and convalescent sera from a COVID cohort (n=124; see methods for cohort description)
1188 with an automatable Luminex bead-based serotest. **B)** Receiver operating characteristic (ROC) curves of
1189 the assayed antigens with an indication of the area under the curve (AUC) and 95% confidence interval
1190 (CI), **C)** Seroreactivity of the two cohorts at a final serum dilution of 1:1,200. Blank-corrected values are
1191 shown. Shades indicate the calculated cut-off yielding a specificity (Sp) of 99.1% for comparison of antigen
1192 performance. P-values were calculated by Mann-Whitney U tests.

1193



1194

1195 **Fig. 2. Convalescent sera from blood donors with mild to moderate courses of disease indicate an**

1196 **advantage of dual-antigen testing and a correlation of tRBD-specific antibodies with SARS-CoV-2**

1197 **neutralization. A-D, A small set of convalescent sera (n=28-31, part of the Medical University of Vienna**

1198 **COVID-19-cohort) with described courses of disease was used for in-depth analysis of the ELISA candidate**


1199 **antigens. Pre-COVID-19 sera included blood donor sera (n=210 and n=14) collected in pre-COVID-19 times**

1200 **(see methods for detailed cohort description). A) Seroreactivity of HEK-tRBD and *E. coli*-derived NP as**

1201 **assessed by the Luminex platform and ELISA at serum dilutions of 1:1,200 and 1:200, respectively, and the**

1202 **cross-platform correlation of the respective readouts. Data give the mean of blank-corrected values from**

1203 three independent production batches. Sensitivities with the respective test antigens at the indicated
1204 pre-defined specificities were calculated by AUC-analysis of ROC curves, P-values were calculated by
1205 Mann-Whitney U tests. **B-C**, Assessment of overlaps in **B**) false-negative and **C**) false-positive serum
1206 samples identified with both the tRBD or NP antigen in the Luminex and ELISA assay. The cut-offs were
1207 set to yield low sensitivity (87.1%, ELISA; 85.,7%, Luminex) or specificity (92.9%, both assays), respectively.
1208 Shades are colored according to the respective antigens (NP: blue, tRBD: pink) and, and indicate the cut-
1209 offs. Numbers in blue and red give the total numbers of false-positives/false-negatives for NP or tRBD,
1210 respectively, while purple numbers give false-positives/negatives identified with both antigens. **D**)
1211 Correlation and partial correlation analysis of ELISA anti-tRBD as well as anti-NP levels with neutralization
1212 titers obtained with authentic SARS-CoV-2 virus. Partial correlations take the effect of antibody levels
1213 towards the respective other antigen into account Individual sera are color-coded according to the course
1214 of disease (green: asymptomatic and mild; black: moderate; red: severe). Solid lines indicate the linear
1215 regression and shades with dotted borders give the 95% CI. Full circles are for sera from individuals with
1216 a PCR-confirmed SARS-CoV-2 infection, open squares indicate asymptomatic close contacts. r_s ,
1217 Spearman's correlation factor.
1218



1219

1220 **Fig. 3. Performance validation of the Technozym NP and RBD tests.** ROC-curve (AUC±95% confidence

1221 intervals) of **A)** the Technozym RBD- and **B)** the NP-ELISA on basis of a cohort of 1,126 pre-COVID-19 and

1222 244 COVID-19 serum samples. **C)** Results from an adaptive orthogonal testing approach, where all samples

1223 yielding <3.000 U/mL in the tRBD ELISA were considered negative and samples with tRBD >35.000 U/mL


1224 positive. Samples with tRBD values between those borders were re-tested with the NP ELISA (blue shade).

1225 If NP>3.500 U/mL, positivity was confirmed, otherwise it was ruled out. Dashed lines indicate the cut-offs

1226 determined by the 99th percentile method (8.000 U/mL) and a reduced cut-off with increased sensitivity

1227 (5.000 U/mL, between 99th percentile- and Youden-index criteria) to display the increase in sensitivity
1228 gained by the orthogonal test system. **D)** Differences in false-positive and -negative test results for
1229 different individual and combined test setups were compared by z-tests, total errors at an estimated 5%
1230 seroprevalence were compared by χ^2 -tests for proportions. * $P<0.05$, ** $P<0.01$, *** $P<0.001$, ****
1231 $P<0.0001$.


1232



1233
 1234 **Fig. 4. Characterization of cross-reactive IgG responses between SARS-CoV-2 and endemic hCoV strains**
 1235 **in the employed specificity cohorts. A)** Seroreactivity of serum samples from the two specificity cohorts
 1236 (AIT pre-COVID-19 cohort, n=210 and MedUni Wien Biobank pre-COVID-19, n=14) employed for pre-
 1237 validation of the SARS-CoV-2 tRBD and NP antigens with the Luminex or ELISA assays respectively, was
 1238 measured with the spike proteins of common-cold hCoVs HKU-1, OC43, 229E and NL63. Outliers were
 1239 classified as observations that fall above the 75th percentile + 1.5 x IQR. Shades give the respective
 1240 calculated cut-offs and are color-coded for NP (blue) or tRBD (pink). Values below the box-plots give the
 1241 measured seroreactivity above these cut-offs in percent. **B)** Relative IgG levels of NP (n=17, blue boxes)
 1242 and tRBD (n=4, pink boxes) outliers towards the spike proteins of hCoV. White boxes give relative IgG

1243 levels of sera with readouts <25th percentile (n=16 for NP, n=5 for tRBD) to compare with outliers. Means
1244 within groups were compared by One-Way ANOVA followed by a Sidak test to correct for multiple
1245 comparisons. **C** tRBD and NP-specific seroreactivity of the specificity cohort (n=1,126 MedUni Wien
1246 Biobank) used for clinical validation. Red crosses display sera from individuals with PCR-confirmed hCoV
1247 infection. Dashed lines indicate the cut-off of 5 U/mL.

1248



1249

1250 **Fig. 5. Time-resolved evaluation of NP, tRBD-specific and neutralizing antibodies in the acute and early**

1251 **convalescent phase after SARS-CoV-2 infection. A-B, A total of 104 plasma samples from 64 outpatients**

1252 **(16%) and hospitalized individuals (65% general ward, ICU 19%) were analyzed for anti-NP and anti-tRBD**

1253 **antibodies and neutralizing antibodies at the indicated time points. A) Antibody levels were assessed with**

1254 **the Technozym ELISAs according to the suggested cut-off of 5.000 U/mL. Bars indicate the fraction of NP,**

1255 **tRBD-positive samples among the tested. Shades give the respective ELISA cut-offs. B) Neutralization**

1256 assays with authentic SARS-CoV-2 virus were performed within a serum dilution range of 1:4 – 1:512
1257 (dashed lines). Values below or above these limits were assigned to 1:2 or 1:1,024 for correlation analysis,
1258 respectively. The red line indicates a NT of 1:160 that is recommended by the FDA for the screening of
1259 recovered COVID-19 patients for convalescent plasma therapy. All sera above this cut-off are color-coded
1260 in red. Geometric mean titers and 95% CI in the RBD ELISA are given for sera with a NT >1:160. r_s ,
1261 Spearman's correlation factor.

1262